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Abstract 
Astrocytes are the most abundant cellular population in the brain and 
their role in neurodegenerative processes is becoming increasingly 
appreciated. In my PhD project, I investigated the contribution of 
astrocytes to neurodegeneration in Multiple Sulfatase Deficiency 
(MS D), a severe Lysosomal Storage Disorder (LSD) caused by 
mutations in the Su/fatase Modifying Factor 1 (SUMF1) gene. Using 
Cre/Lox mouse models, I found that astrocyte-specific deletion of 
Sumf1 in vivo induced severe lysosomal storage and autophagy 
dysfunction with consequential cytoplasmic accumulation of toxic 
substrates. Lysosomal storage in astrocytes was sufficient to induce 
degeneration of cortical neurons in vivo, whereas other neuronal 
populations were spared. Furthermore, in an ex vivo co-culture assay, I 
observed that Sumfr'- astrocytes failed to support the survival and 
function of wild type cortical neurons, suggesting a non-cell 
autonomous mechanism for neurodegeneration in LSDs. Compared to 
the astrocyte-specific deletion of Sumf1, the concomitant deletion of 
Sumf1 in both neurons and glia in vivo induced a widespread neuronal 
loss and robust neuroinflammation. Finally, behavioural analysis of 
mice with astrocyte-specific deletion of Sumf1 compared to mice with 
Sumf1 deletion in both astrocytes and neurons allowed me to link a 
subset of neurological manifestations of LSDs to astrocyte dysfunction. 
This study indicates that astrocytes are integral components of the 
neuropathology in LSDs and that modulation of astrocyte function may 
impact the disease course. 
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Introduction 
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1.1 Sulfatases and human diseases 
Sulfatases are a family of enzymes that catalyze the hydrolysis of 
sulfate ester bonds, such as O-sulfates and N-sulfates, from a wide 
variety of substrates, ranging from complex molecules, such as 
glycosaminoglycans, to sulfolipids and steroid sulfates. The general 
reactions catalized by sulfatases are: 
R-OS03 - + H20 --+ R-OH + H+ + S042-
R-NHS03- + H20 --+ R-NH3++ sol-
Sulfatases are found in most species from bacteria to eukaryotes and 
share the following features: (a) they have a similar size, ranging from 
500 to 800 amino acids, (b) they are extensively glycosylated, (c) they 
share significant sequence homology over their entire length, and in 
particular in the N-terminal region, and (d) they have a highly similar 
active site, which undergoes a unique posttranslational modification 
(Sardiello et al., 2005). 
Figure 1.1 shows the sequence alignment of all 17 human sulfatases in 
three regions, which represent highly conserved protein domains 
(domains a, b, and c). 
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a b 
ARSC PNIILVKADDLGIGDPG 43 ARSC ASPLCTPSRAAFMTORYPV 89 
ARSD P~TLLlNADDLGTGDLG 57 ARSD AAPLCTPSRAAFLTORHSF 103 
ARSB PNIVLLMADDLGVGDLC 23 USR AASMCTPSRAAFL7CRYPI 69 
AllSE PNILLLMADDLGIGDIG 54 ARS!! AASLCTPSRAAFLTOIlYPV 100 
AllSP PNIVLIKVDDLGIGDLG 47 AIlSI'" AASLCSPSRSAPLTGIlYPI 93 
ARBO PNFVlILADDMGWGDLG S2 ARSG AASl'CSPSJlASLLTOJlLGL 98 
AIISA PNIVLIFADDLGYGDLG 37 AJtlIA PVSLCTPSIlAALLTGIlLPV 83 
GALNS PNILLLLMDDMGWGDLG 47 GALMS ANPLCSPSRAALLTORLPI 93 
ARSB PBLVFLLADDLGWIfDVG 61 ARSB TQPLCTPSRSQLLTGRfQI 105 
AllSJ PRLIPlLADDQGPRDVG 92 AItSJ VQPICTPSRSQFITGKYQI 136 
AlIBI PHIIFILTDDQGYBDVG 63 AIlSI IQPICTPSIlSQLLTORYQI 107 
SGSH IUl'ALLLLADDGGFESGA 39 SGSH SVSSCSPSJlASLLTOLPQH 84 
GNS PNVVLLLTDDQDEVLGG 63 ONS PSALCCPSRASILTGKYPH 105 
SULFl PNIILVPTDDQDVBLGS 59 SULPl TTPHCCPSIlSSHLTOKYVB 101 
SULF2 PNIILVLTDDQDVELGS 60 SULl"2 TTPHCCPSRSSILTOKYVB 102 
TSIJLF PNVVLVVSDSFDGRLTF 48 TSULl" NSPICCPSRAAMWSGLFTB 94 
IDS LNVLLIIVDDLRPSLGC 53 IDS QQAVCAPSIlVSFLTORRPD 98 
C ARSC XDQGISTALIGKWBLGKB 140 
ARSD OQBGIATGLIGIOIBQGVN 154 
lUlS8 Q81lGIRTGLIGKWHLGLS 121 
ARSE KBKGfATGLICKWRLCLH 151 
ARSI" XKQGYSTGLIGKWHQGLN 144 
ARSG OQACYVTGIIGKWRLCBH 143 
AIlSA AARGYLTGHllGKWBLOVG 129 
GALNS XKAGYVSKIVGIOIBLGBR 146 
ARSB KBIIGYTTHKVGKIilILGKY 151 
AIlSJ KKVGISTHMVGKWHLGFY 182 
ARSI QEAGYSTHMVGKWRLCFY 153 
SlOSH SQAGVRTGIIGKKHVGPE 129 
GNS SHCGIQTFFAGKYLNBIG 155 
SVLFl NNTGYRTAFFGKYLNIIYN 148 
SVLF2 NSTGIRTAFFGKYLNIIYN 149 
TSULP' ERBGIRTQKrGKLDYTSG 134 
:IDS XEBGYV'DISVGKVPBPGI 141 
Figure 1.1: Sequence alignment of conserved domains among human 
sulfatases. (a) and (c) represent domains from the N-terminal of the proteins. (b) 
represents the active site. Shaded amino acids are conserved in 90% of all 
sulfatases. The asterisks mark the amino acids with a known catalytic function. 
Reproduced from (Diez-Roux and Ballabio, 2005) 
3 
Sulfatases present different substrate specificities and can be divided, 
at least in mammals, into two main categories based on their 
subcellular localization: those acting at an acidic pH, localized in the 
Iysosomes, and those acting at a neutral pH that are found in the 
endoplasmic reticulum (ER), in the Golgi apparatus, and at the cell 
surface (Table 1.1). The lysosomal sulfatases are involved in catabolic 
cellular functions, whereas the functions of the non-lysosomal 
sulfatases is less clear (Parenti et al., 1997; Hanson et al., 2004; Diez-
Roux and 8allabio, 2005). The only sulfatase in this category whose 
metabolic role has been thoroughly characterized is the steroid 
sulfalase (STS/ARSC), which is involved in the biosynthesis of several 
steroid molecules (8allabio A, 2001). 
In addition SULF1 and SULF2, two newly identified sulfatases, are 
located on the cell surface where exert the desulfation of extracellular 
heparan sulfate proteoglycan, whose sulfation state influences the 
binding of signaling molecules to their receptor (8ulow and Hobert, 
2006). Furthermore the expression of these sulfatases is 
developmentally regulated, therefore, they specify a novel functional 
category within the sulfatase family that is involved in cell signaling and 
embryonic development (Dhoot et al., 2001). 
Mutations in many sulfatase genes are responsible for different human 
4 
genetic disorders (Neufeld EF, 2001a; Von Figura K, 2001 )(Table 1.1). 
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G~lk l-:llZ}lUl' 
A RS.4. 
ARSB 5qB ArylsulfAt B Ly 0&0111111 Mar teaux-Lamy 
syndrome (MPSV}l 
lDS Xq27-28 Iduronal Lyso orn.tl Hunter syndrom 
Sulfalase MP ID 
SGSH I7q2SJ SuJfarnidase lyso omal S:tnfili ppo A 
syndronJe MPSUlA 
G6S I1ql4 Glu('osamine. Lysosonul Sanfilippo D 
6-SulfalU~ syndrome (J\,tPSTlIO) 
GAI..6S 16q24 Galacto ~.6· Lyso!;omal Morquio A l)lJldrom 
Sulfmas CMPSTVA 
.4 RSClSTS Xpll.3 Aryl::;ulfllt, Micl'Ol>ornaJ X-linked Iclllh 'osis 
aSti!roid (XU 
sulf'3wC 
.4RSD Xp22.3 Arylsulf.lt D ER NI 
AR E Xp213 Arylsulf t ~ E G ISi Ch od Y'pla ill 
Puoct la 1 (CDPXI 
ARSF Xp22.3 Arybulf.:ttase F ER NI 
ARSIP Xp22.3 Arylsulf iase H ND NI 
H VU) SqI.:t2-13.3 Hsulfl Cell surf re NI 
H VLFl 1Oq13.12 Rc.ulf2 Cell ~urfare NI 
MSC 17q23-24 Aryl ulfllt se G ER NI 
ARSJb 4q26 Ary /sui r lit J ER N1 
ARSJb Sq32 Arylsulf:llUSt> K ER NI 
TSVLP Sql5 T. Sulf31ru;e NO NJ 
Table 1.1: Main characteristics of human sulfatases. Reproduced from (Diez-
Roux and Ballabio, 2005) 
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1.2. Deficiency of lysosomal sulfatases 
In human the deficiency of a given lysosomal sulfatase causes a block 
in the catabolic pathway involved in the degradation of complex 
sulfated macromolecules, such as glycosaminoglycans (GAGs) and 
sulfated glycolipids, with their consequent accumulation in cells and 
tissues. The phenotypic consequences depend on type and tissue 
distribution of the accumulating substrate. These diseases belong to 
the lysosomal storage disorders, a group of genetic diseases 
characterized by the accumulation of undigested material inside cells 
and tissues due to lysosomal dysfunction (Cox and Cachon-Gonzalez, 
2012). Namely, sulfatase deficiencies are associated to Metachromatic 
Leukodystrophy (MLO) and to five different types of 
Mucopolysaccharidoses (MPS 11, iliA, 1110, IVA, and VI) (Table 1.2). 
MLO is an autosomal recessive disorder with an estimated frequency 
of 1 in 40,000 births. MLO is caused by loss-of-function mutations of 
the Ary/sulfatase A (ARSA) gene that codes for a sulfatase normally 
deputed to the desulfation of glycolipids, such as sulfatides, inside the 
lysosome (Von Figura K, 2001 ). Sulfatides are an important 
component of the myelin sheath (a fatty layer covering the nerve 
fibers), produced by oligodendrocytes in the central nervous system 
and by Schwann cells in the peripheral nervous system (Abe and 
7 
Norton, 1974); (Benjamins et al., 1974). Without a functional ARSA, 
sulfatides accumulate in the cytoplasm of oligodendrocytes and 
Schwann cells causing their dysfunction and, in turn, the progressive 
de-myelination of nerve fibers. The symptoms of the disease are 
progressive and include gait disturbance, mental regression, loss of 
speech, optic atrophy, ataxia, and spastic tetraparesis. 
The term Mucopolysaccharidoses (MPS) refers to a group of 
lysosomal storage disorders caused by deficiency in enzymes 
catalyzing the stepwise degradation of glycosaminoglycans (GAGs) 
(formerly called mucopolysaccharides) (Neufeld EF, 2001b). The 
GAGs represent the sugar moiety of the proteoglycans that are a major 
component of the extracellular matrix. the "filler" substance existing 
between cells. Proteoglycans are involved in a wide variety of functions 
ranging from the binding of cations and water to regulating the 
movement of molecules. Evidence also shows they can affect the 
activity and stability of proteins and signalling molecules within the 
matrix. Individual functions of proteoglycans can be attributed to either 
the protein core or the attached GAG chain (Bulow and Hobert, 2006). 
Glycosaminoglycans are large linear polysaccharides constructed of 
repeating disaccharide units with the primary configurations containing 
8 
an amino sugar (either N-Acetylglucosamine or N-
Acetylgalactosamine) and an uronic acid (either glucuronic acid and/or 
iduronic acid). There are five identified glycosaminoglycan chains: 
hyaluronan; chondroitin; dermatan; heparin/heparin; keratin. 
Hyaluronan is not sulfated, but the other glycosaminoglycan chains 
contain sulfate residues at various positions of the chain. Various 
degrees of sulfation occur at the oxygen and/or nitrogen containing 
groups, on each monosaccharide unit (Bulow and Hobert, 2006). GAG 
desulfation, a necessary step for their degradation, is exerted by 
sulfatase inside the lysosome. 
To date the deficiency of five sulfatases are associated to a specific 
type of MPS: iduronate sulfatase to MPS 11 (Hunter syndrome); 
heparan N-sulfatase to MPS iliA (Sanfilippo A syndrome); N-
acetlyglucosamine 6-sulfatase to MPS IIID (Sanfilippo D syndrome); 
galactose 6-sulfatase to MPS IV A (Morquio A syndrome); N-
acetylgalactosamine 4-sulfatase to MPS VI (Maroteaux-Lamy 
syndrome) (Neufeld EF, 2001b). All are transmitted in an autosomal 
recessive manner, except for MPS 11, which is X linked. 
All MPSs display a complex phenotype with involvement of several 
tissues and organs, a progressive course of the disease, and a great 
9 
variability in the expression of the symptoms. These include, in 
different combinations, facial dysmorphisms, skeletal deformities, 
hepatosplenomegaly, joint and skeletal abnormalities, corneal 
clouding, hearing defects, respiratory and cardiovascular defects, 
mental retardation, and neurological abnormalities. Profound mental 
retardation is characteristic of the severe form of Hunter syndrome and 
all subtypes of Sanfilippo syndrome, which is characterized by severe 
central nervous system degeneration (Neufeld EF, 2001 b) (Table 1.2). 
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Table 1.2: Diseases due to single sulfatase deficiencies. Reproduced from 
(Diez-Roux and Ballabio, 2005) 
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1.3 Deficiency of non-lysosomal sulfatases 
This category includes two disorders (both X-linked) caused by 
deficiencies of sulfatases located in cellular compartments other than 
Iysosomes and acting at a neutral rather than an acidic pH. 
One of them is the steroid sulfatase (STS). This enzyme is localized 
primarily in the ER and is involved in the desulfation of steroid sulfates, 
the reservoir or a source of precursors for producing active hormones. 
STS deficiency is the biochemical hallmark of an inherited skin disease 
called X-linked ichthyosis (XLI), whose major feature is the presence of 
dark scaly skin (Marinkovic-Ilsen et al., 1978) (Table 1.2). Interestingly, 
babies affected by this disease are usually born by caesarean section 
due the lack of production of estriol by the placenta caused by STS 
deficiency, leading to refractoriness to the onset of labor (also 
described as uterine inertia) (France and Liggins, 1969). Affected 
babies appear normal at birth, and the placentas lack anatomic 
defects. Ichthyosis becomes apparent in STS-deficient babies between 
o to 3 months and slightly improves with age. The scales are due to an 
altered cholesterol sulfate/cholesterol ratio in the stratum corneum of 
the epidermis (France et al., 1973). 
The second disorder due to deficiency of a non-lysosomal sulfatase is 
Chondrodysplasia punctata 1 (CDPX1), a congenital defect of bone 
12 
and cartilage development characterized by aberrant bone 
mineralization manifested by punctate calcification of bone epiphyses, 
severe underdevelopment of nasal cartilage, and distal phalangeal 
hypoplasia (Table 1.2). The gene mutated for CPDX1 is Ary/sulfatase 
E (ARSE) (Franco et al., 1995). The ARSE protein is located in the 
Golgi apparatus but its natural substrate has not yet been identified 
and therefore its metabolic function remains elusive. 
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1.4 Posttranslational modification of sulfatases and Multiple 
Sulfatase Deficiency 
To be active, sulfatases require a critical post-translational modification 
that occurs before their targeting to different cellular compartments, 
consisting of the conversion of a cysteine residue located within their 
active site into a 2-amino-3-oxopropanoic acid [a-formylglycine (FGly)] 
(Schmidt et al., 1995). The modified cysteine residue is highly 
conserved across evolution, and is present in all sulfatases (Sardiello 
et al., 2005)(Fig 1.1 b). 
The enzyme responsible for sulfatase activation is known as 
formylglycine-generating enzyme (FGE) (Cosma et al., 2003) (Dierks 
et al., 2003). The FGE is located into the ER and it recognizes a short 
sequence motif, C-[TSAC]-PSR, which is necessary and sufficient for 
specific FGE-sulfatase interaction within the ER immediately after 
sulfatase translation (Roeser et al., 2006) 
The gene encoding FGE is the Su/fatase Modifying Factor 1 (SUMF1) 
gene and when mutated it is responsible for a severe form of 
lysosomal storage disorder known as Multiple Sulfatase Deficiency 
(MSD) (Cosma et al., 2003) (Dierks et al., 2003) (Cosma et al., 2004; 
Dierks et al., 2005; Schlotawa et al., 2011). MSD is extremely rare 
(1 :1.4million births), and it is transmitted in an autosomal recessive 
14 
manner. At biochemical level, MSD is characterized by a profound 
impairment of all sulfatase activities that in turn lead to intracellular 
accumulation of the sulfatase substrates (Figure 1.2). As a 
consequence, the phenotype of MSD patients combines all the clinical 
symptoms observed in individual sulfatase deficiencies (Table 1.2) 
such as ataxia, progressive loss of motor, speech, vision and hearing 
abilities, hepatosplenomegaly, dysostosis multiplex, abnormal facies, 
stiff joints, and ichthyosis. The patients usually die within the first 
decade of life (Hopwood JJ, 2001). 
15 
ER Golgi Lyso om 
SUMF1 gentt 
- -----
Figure 1.2: Mutations in the Su/fatase Modifying Factor-1 (SUMF1) gene 
result in the production of defective a-formylglycine-generating enzyme 
(FGE). Defective FGE cannot convert the cysteine (Cys) residue that is found at 
the active site of lysosomal sulfatases to a -formylglycine (FGly). As a result, 
inactive sulfatases are transported to the lysosome, where they are unable to 
degrade various sulfate esters . This leads to sulfate-ester accumulation and 
subsequently to MSD. ER, endoplasmic reticulum . Reproduced from (Futerman 
and van Meer, 2004) 
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1.5 Identification of SUMF1 gene 
The SUMF1 gene was identified with two completely independent and 
complementary approaches, one biochemical and the other genetic. 
Dierks et al. (Dierks et al., 2003) used a biochemical approach to purify 
the FGE by developing a peptide-based assay for FGE activity. This 
assay was based on a 23-mer peptide from the ARSA amino acid 
sequence that was recognized by the FGE machinery. Purification of 
FGE from the soluble fraction of bovine testis microsomes was 
performed utilizing a four-step chromatography. The resulting peptides 
were subjected to peptide mass fingerprint analysis, leading to the 
amino acid sequence of FGE and to the discovery of the 
corresponding cDNA in expressed sequence tag (EST) databases. 
This cDNA was found mutated in patients with MSD. 
A genetic complementation approach was used by Cosma et al. 
(Cosma et al., 2003), who performed microcell-mediated chromosome 
transfer to identify the gene complementing the enzymatic deficiency in 
MSD. A panel of human/mouse hybrid lines containing individual 
normal human chromosomes, tagged with two selectable markers, was 
the source of donor human chromosomes and was fused to an 
immortalized cell line from a patient with MSD. All 22 human 
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autosomes were transferred one by one and the resulting colonies 
tested for sulfatase enzymatic activity. This analysis allowed the 
assignment of the gene to chromosome 3. Then, irradiation followed by 
microcell-mediated chromosome transfer allowed mapping of the 
complementing gene to a smaller chromosomal region, spanning 
approximately 2.4Mb. All genes located in this region were tested for 
mutations in MSD patients until one of them was found mutated in all 
patients tested. 
SUMF1 is both an essential and a limiting factor for the activity of 
sulfatases (Fig 1.3). In normal condition the amount of SUMF1 is 
sufficient for the post-translational activation of all sulfatases (Fig 
1.3A). In MSD patients the lack of SUMF1 results in inactive sulfatases 
(Fig 1.38). Due to a limited availability of SUMF1, the overexpression 
of a sulfatase only partially increases the sulfatase enzymatic activity 
despite the amount of protein produced (respectively, smaller circle 
and larger circle in Fig 1.3C). An increase in a sulfatase enzymatic 
activity occurs only when this is co-expressed with SUMF1 (large circle 
in Fig1.3D) (Cosma et al., 2003). 
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Figure 1.3: SUMF 1 is an essential limiting factor for the activity of 
sulfatases. (A) SUMF1 activates sulfatases in physiological conditions . (8) If 
SUMF1 is mutated, as in MSO, the activity of all sulfatases is impaired. (C) If a 
sulfatase is overexpressed , the activity is partial (smaller circle) relative to the 
amount of protein produced (larger circle) due to the limiting amount of SUMF1 
protein . (0) A complete activation of a sulfatase (large circle) only occurs when 
both the sulfatase and SUMF1 are overexpressed . Reproduced from (Cosma et 
al ., 2003) 
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1.6 The MSD mouse model 
In order to study the pathological mechanisms leading from sulfatase 
impairment to the MSD phenotype a mouse line with genetic deletion 
of Sumf1 was generated (Settembre et al., 2007). Sulfatase activities 
were completely absent in Sumf1-I- mice, indicating that Sumf1 is 
indispensable for sulfatase activation and that mammals have a single 
sulfatase modification system. Similarly to MSD patients, Sumf1-I- mice 
displayed frequent early mortality, congenital growth retardation, 
skeletal abnormalities, and neurological defects. All tissues examined 
showed progressive cell vacuolization and significant lysosomal 
storage of GAGs. The prominent and progressive neurodegeneration 
was characterized by remarkable neuronal cell loss associated with 
activated microglia and astroglyosis throughout the brain. 
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1.7 Neuropathological mechanisms in MSD 
1.7.1 Impaired autophagy 
As for many other LSDs, progressive and severe neurodegeneration is 
a prominent feature of MSD (Platt FM, 2004). Previous studies 
identified impaired autophagy in neurons as a crucial component in the 
pathogenic mechanisms leading to neurodegeneration in MSD as well 
as in other LSDs (Settembre et al., 2008b). 
During autophagy a large portion of the cytosol is sequestered in 
specific vesicles (autophagosomes, AVs) and then degraded upon 
fusion with Iysosomes. Through basal autophagy the cell regulates 
turnover of organelles, such as mitochondria, peroxisomes and 
endoplasmic reticulum. Beyond the basal activity, autophagy can be 
induced as response to many adverse circumstances: during nutrient 
depletion autophagy allows generation of ATP from the catabolism of 
macromolecules; during oxidative stress, induction of autophagy allows 
the efficient removal of damaged organelles and proteins from the 
cytoplasmatic environment, acting as a pro-survival pathway 
(Ravikumar et al., 2006). 
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Lysosomal storage may dampen the last steps of the autophagic 
process. A defective autophagy in LSDs was proposed to be a 
consequence of an impaired Iysosome-autophagosome fusion. 
Settembre et al., showed a decreased co-localization of the lysosomal 
marker LAMP1 with the autophagosomal marker LC3 in MSD mouse 
embryonic fibroblasts (MEFs) compared with wild-type cells 
(Settembre et al., 2008b). Fraldi et al., confirmed and extended this 
observation using a tandem fluorescent-tagged autophagosomal 
marker in which LC3 was engineered with both the monomeric red-
fluorescent protein (mRFP) and the green fluorescent protein (GFP) 
tags. The quenching of GFP fluorescence into the intra-lysosomal 
acidic pH allowed to measure the rate of autophagosome fusion with 
lysosome. This rate was found markedly slower in MSD cells 
compared with WT cells. The decreased fusion was also confirmed in 
MEFs isolated from another type of LSD, the MPSIIIA (Fraldi et al., 
2010). Furthermore, studies performed on cells isolated from patient 
affected from a different type of LSD (Mucolipidosis type IV) also 
demonstrated an impairment of fusion of late endosomes/lysosomes 
(CD63 signal) with LC3-positive vesicles (Vergarajauregui et al., 2008). 
Other evidences suggest that in cells affected by LSD the lysosome, 
upon fusion with autophagosome, cannot degrade the autophagic 
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content leading to cytosolic accumulation of large 
autophagolysosomes. One unifying possibility could be that the 
incomplete autophagic degradation inhibits the autophagic lysosome 
reformation (ALR) process, through which the cell restores its pool of 
Iysosomes (Yu et al., 2010). This block, in turn, may lead to a 
lysosomal depletion that slower the fusion efficiency between newly 
generated autophagosomes and Iysosomes. 
Indeed, autophagosome accumulation was found in neurons from the 
mouse model of MSD and other LSDs, associated with the 
accumulation of autophagy substrates, such as poliubiquitinated 
proteins and aberrant mitochondria (Settembre et al., 2008b). This 
evidence suggests that the secondary accumulation of autophagic 
substrates may have a role in LSD pathogenesis. Many of the proteins 
that cause late-onset neurodegenerative conditions, such as 
Huntington's and familial forms of Parkinson's diseases, are autophagy 
substrates (Rubinsztein, 2006). Thus, autophagy dysfunction 
represents an important pOint of intersection between lysosomal 
storage diseases and more common types of neurodegenerative 
diseases. 
23 
1.7.2. Neuroinflammation 
Another point of intersection between lysosomal storage diseases and 
neurological disorders such as Alzheimer's disease (Tuppo and Arias, 
2005), Amyotrophic lateral sclerosis (McGeer and McGeer, 2002), 
Parkinson's disease (Tansey and Goldberg, 2010) and Prion diseases 
(Perry et al., 2002) is the mounting of an atypical inflammatory 
response that is mediated by microglia and astrocytes in the innate 
immune system. The principal mechanism through which an innate 
immune response is initiated, involves signalling through the TLR 
family of receptors (Crack and Bray, 2007). It has become clear that 
injured cells, including neurons (Sloane et al., 2010), release a class of 
molecules known as "danger associated molecular pattern" (DAMP) 
ligands that bind to TLR receptors present on microglia and initiate an 
innate immune response. Activated microglia may exhibit behaviours 
associated with anti-inflammatory macrophages, secreting molecules 
that promote tissue repair and internalizing cellular debris, including 
aggregated, misfolded proteins, such as b-amyloid, through 
phagocytosis. Alternatively, responding microglia may adopt a pattern 
of behaviour similar to pro-inflammatory macrophages as they release 
molecules intended to protect against pathogens, including neurotoxic 
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cytokines, reactive oxygen species (ROS), and small molecules, such 
as quinolinic acid, that promote excitotoxicity (Colton, 2009). The 
release of cytokines and chemokines can lead to the recruitment of 
additional inflammatory cells (macrophages) from adjacent blood 
vessels, and may also engage astrocytes in the proinflammatory 
response. Activation of astrocytes induces astrogliosis, which is 
characterized by altered gene expression, hypertrophy, and 
proliferation (Ridet et al., 1997). Activated astrocytes can release a 
wide array of immune mediators such as cytokines, chemokines, and 
growth factors, that may exert either neuroprotective or neurotoxic 
effects (Farina et al., 2007). In conclusion, neuroinflammatory 
responses to neuronal dysfunction in neurodegenerative disorders 
present a complex nature, being potentially beneficial or detrimental 
depending on the fine balance between a number of factors, including 
the type, the duration and the severity of the insult and the complex 
interplay between the various cytokines released by microglia and 
astrocytes and their receptors. 
However, the molecular event triggering microglia and astrocyte 
activation in lysosomal storage disorders may be more ambiguous. 
Microglia and astrocytes store undigested material in their cytoplasm 
2S 
(Settembre et al., 2007); this storage may alter their physiological 
state, hence trigger their activation and, consequently, drive 
neuroinflammation. 
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1.7.3. Proposed model for the pathogensis of LSDs 
A possible model for the pathogenesis of MSD and LSDs in general 
has been proposed (Figure 1.4). According to this model the lysosomal 
storage leads to a block of the autophagic flux causing a secondary 
accumulation of autophagy substrates such as polyubiquitinated 
proteins, p62/SQSTM1 and dysfunctional mitochondria in different cell 
types, included neurons (Lieberman et al., 2012). The accumulation of 
these secondary substrates is reported to be toxic for the cell and may 
contribute to cell death. The inflammatory response to cell damage 
may further exacerbate the phenotype (Fig 1 .4) (8allabio and 
Gieselmann, 2009). This model suggests how neuronal cell loss, 
hence, neurodegeneration, proceeds in MSD. To date, research has 
focused on neurons, however glia cells are affected by the same 
genetic defect and impairment of their function may significantly 
contribute to the neuronal dysfunction observed in MSD. 
27 
onclary 
to 9 
Figure 1.4: A proposed model for the pathogenesis of LSDs. Adapted from 
(Ballabio and Gieselmann, 2009) 
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1.8 Brain cell types 
The brain is composed of two broad classes of cells: neurons and glial 
cells (Eric R. Kandel, 2000). 
Neurons are electrically excitable cells that process and transmit 
information by electrical and chemical signaling. Chemical signaling 
occurs via synapses, complex membrane junctions that transmit 
signals to other cells. A typical neuron possesses a cell body (often 
called soma), dendrites, and an axon. At the majority of synapses, 
signals are sent from the axon of one neuron to a dendrite of another, 
in this way neurons connect to each other to form neural networks. 
Glial cells, sometimes called neuroglia, are the non-neuronal cells of 
the central nervous system (CNS). The term glia (from the Greek word 
meaning "glue") reflects the nineteenth-century presumption that these 
cells held the nervous system together in some way. The word has 
survived, despite much more complex roles have been recognized to 
glia. 
There are three types of glial cells in the mature central nervous 
system: astrocytes, oligodendrocytes, and microglial cells. 
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• Astrocytes main function is to maintain, in a variety of ways, an 
appropriate chemical environment for neuronal signaling. 
Because of the interest for this thesis work, the next paragraph is 
aimed to elucidate astrocyte morphological features and 
functions. 
• Oligodendrocytes lay down a laminated, lipid-rich wrapping 
called myelin around neuronal axons. This has important effects 
on the speed of action potential conduction. 
• Microglial cells, as the name implies, are the smaller cells among 
glia, and they derive from hematopoietic stem cells. They share 
many properties with tissue macrophages, and are primarily 
scavenger cells that remove cellular debris from sites of injury or 
normal cell turnover (Eric R. Kandel, 2000). 
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1.9 Astrocytes 
Astrocytes are the most abundant cell type in the mammalian brain. 
They greatly outnumber neurons, and are organized into discrete 
subdivisions at the anatomical level, within which as many as 100,000 
synapses can be located (Benarroch, 2005). In such regions, 
astrocytes extend their cell membranes into and among neuronal 
synapses, forming closely interdigitating areas of direct apposition. In 
addition, astrocytes project specialized endfeets in close contact with 
intraparenchymal blood vessels, almost entirely covering their surface 
(Benarroch, 2005). 
These features, ideally position astrocytes to play crucial roles in adult 
eNS homeostasis, performing a variety of functions reflecting their 
communication and close interaction with neurons (Belanger and 
Magistretti, 2009). 
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1.9.1 Astrocyte classification 
Morphologically, astrocytes may be distinguished based on the 
location in the white versus the gray matter. 
Fibrous astrocytes populate the white matter. They typically have 
regular contours and cylindrical processes, yielding the more classic 
"starlike" appearance, and have dense glial filaments that stain with 
the intermediate filament marker GFAP (glial fibrillary acidic protein). 
Protoplasmic astrocytes populate the gray matter and have more 
irregular processes and few glial filaments (Vaughn and Pease, 1967; 
Vaughn and Peters, 1967; Bignami et al., 1972; Freeman, 2010). 
Protoplasmic astrocytes contact and sheathe synapses by extending 
thousands of thin processes, with typically only one or two in contact 
with blood vessels or CNS boundaries (Reichenbach et al., 2010) 
(Figure 1.5). 
In addition, there are two types of specialized astroglia: Bergmann glia 
in the cerebellum, with cell bodies in the Purkinje cell layer and 
processes that extend into the granule cell layer, and Muller glia in the 
retina, whose cells are oriented radially, spanning the photoreceptor 
layer to the inner retinal surface. Both of these cell types are 
morphologically reminiscent of the radial glia cells present during CNS 
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development. However, in the adult eNS, the Bergmann and Muller 
glia are thought to functionally resemble protoplasmic astrocytes in that 
they associate with and enwrap synapses and may act to modulate 
synaptic function (Reichenbach et al., 2010). 
33 
Figure 1.5: Astrocytes are morphologically heterogeneous. (Left) a 
protoplasmic astrocyte is shown in close connection with a neuron and a capillary, 
constituting the so-called "neurovascular unit" and highlighting the roles of 
astrocytes in developmental synaptogenesis and modulating the blood 
brainbarrier. (Right) a fibrous astrocyte is shown in a white matter tract, where it 
may interact with oligodendrocytes to promote myelination. Reproduced from 
(Molofsky et aI. , 2012) 
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1.9.2 Astrocyte functions 
1} Glutamate uptake and recycling 
Glutamate is the primary excitatory neurotransmitter in the brain and 
overstimulation of glutamate receptors is highly toxic to neurons 
(Sattler and Tymianski, 2001). While basal extracellular glutamate 
levels are maintained in the low micromolar range, they increase 
dramatically during glutamatergic neurotransmission, reaching up to 1 
mM in the synaptic cleft. This concentration would cause extensive 
neuronal injury in the absence of highly efficient mechanisms for its 
removal at the synapse (Clements et al., 1992). Indeed, activation of 
the glutamate receptors on neuronal surface results in the opening of 
an ion channel non-selective to cations. Therefore, persistent 
activation of postsynaptic receptors drives excess Ca2+ into neurons, 
resulting in "excitotoxicity" that culminate in neuron cell death, once 
the capacity of the neuron to safely sequester Ca2+ is exceeded. 
Glutamate uptake from the synaptic cleft is primarily accomplished by 
the astrocyte-specific sodium-dependent high-affinity glutamate 
transporters GL T-1 and GLAST (corresponding to human EMT2 and 
EM T1, respectively) and to a lesser extent by the neuronal glutamate 
transporters EAAC1 (human EAAT3) and EMT4 (Danbolt, 2001). 
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Indeed, knockout mice for GL T-1, considered the main astrocytic 
glutamate transporter (it exerts the 90% of glutamate removal), suffer 
lethal spontaneous seizures and selective hippocampal neuronal 
degeneration (Tanaka et al., 1997), whereas knockout mice for the 
neuronal EMC1 display no apparent neurodegeneration (Peghini et 
al., 1997). Astrocytes also play a central role in the transfer of 
glutamate back to neurons following its uptake at the synapse. Failure 
to do so would result in the rapid depletion of the glutamate pool in 
presynaptic neurons and subsequent disruption of excitatory 
neurotransmission. This transfer is achieved by the glutamate-
glutamine cycle (8ak et al., 2006; McKenna, 2007). In short, glutamate 
is converted to glutamine by the astrocyte specific enzyme glutamate-
ammonia ligase (GLUL) (Norenberg and Martinez-Hernandez, 1979). 
Glutamine is then transferred to neurons where it is converted back to 
glutamate via deamination by phosphate-activated glutaminase, which 
is enriched in the neuronal compartment (Bak et al., 2006). Astrocytes 
are also responsible for the replenishment of brain glutamate, as they 
are the only neural cell type expressing pyruvate carboxylase, a key 
enzyme allowing them to synthesize glutamate from glucose (Yu et al., 
1983) (Figure 1.6, pink box). 
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2) K+ buffering 
Neuronal activity and the resulting propagation of action potentials 
causes substantial local increases of extracellular potassium ions (K+) 
in the restricted extracellular space. Astrocytes are responsible for K+ 
buffering through the Na+/K+ ATPase pump that enables astrocytes to 
uptake the excess extracellular K+. This, can then travel in the 
astrocyte syncytium through gap junctions from areas of high 
concentration to areas of lower concentration and finally be extruded 
into the extracellular space or the circulation (Kofuji and Newman, 
2004) (Figure 1.6, orange box). 
3) Supply of energy substrates 
Neurons have very high energy requirements to maintain the steep ion 
gradients necessary for the transmission of action potentia Is (Sokoloff, 
1999). Although neurons can import glucose directly from the 
extracellular space, astrocytes have been proposed to play an 
instrumental role in coupling neuronal activity and brain glucose uptake 
through a mechanism referred to as the astrocyte-neuron lactate 
shuttle (ANLS) (Pellerin et al., 2007). In brief, glutamate uptake by 
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astrocytes is accompanied by Na + entry, which is counteracted by the 
action of the Na+/K+ ATPase. The resulting increase in ADP/ATP ratio 
triggers anaerobic glycolisis in astrocytes and glucose uptake from the 
circulation through the glucose transporter GLUT1, expressed 
specifically by glial and capillary endothelial cells in the brain. Lactate 
produced by astrocytes as an end result of glycolysis is released into 
the extracellular space and taken up by neurons. Once into neurons, 
lactate can be used as an energy substrate via its conversion to 
pyruvate by the action of lactate dehydrogenase and subsequent 
oxidation in the mitochondrial TeA cycle. Another key feature of 
astrocytes is their capacity to store glucose in the form of glycogen. 
Indeed, in the eNS glycogen is almost exclusively present in 
astrocytes and virtually constitutes the only energy reserve (Brown and 
Ransom, 2007) (Figure 1.6, blue boxes). 
4) pH buffering 
Several neuronal processes are strongly affected by relatively small 
shifts in pH, including energy metabolism, membrane conductance, 
neuronal excitability, synaptic transmission, and gap junction 
communication (Obara et al., 2008). Glial cells (in this case astrocytes 
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and oligodendrocytes), present a high pH buffering capacity, due to 
their enriched expression of carbonic anhydrase (CA), which converts 
CO2 into H+ and HC03- effectively allowing them to act as a CO2 sink. 
Indeed, during periods of high neuronal activity, the CO2 produced by 
elevated oxidative metabolism diffuses into glial cells and is converted 
to H+ and HC03- by the action of glial CA. Two HC03- can then be 
transported into the extracellular space along with one Na+ via the 
Na+/HC03- cotransporter (NBC), thereby increasing the extracellular 
buffering power. The protons left in the glial compartment can be used 
to drive the transport of lactate outside of astrocytes through 
monocarboxylate transporter (MCT) -1 and -4 and its subsequent 
transport by MCT-2 into neurons, since MCTs exploit proton gradients 
for the transport of lactate (Deitmer, 2002) (Figure 1.6, yellow box). 
5) Defense against oxidative stress 
Neuronal activity is associated to a high rate of oxidative energy 
metabolism, which inevitably generates reactive oxygen species 
(ROS). However, neurons present a low intrinsic antioxidant capacity, 
indeed, they are supported, also in this function, by astrocytes which 
display a much more effective artillery against ROS (Wilson, 1997). 
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Glutathione (GSH) is the most important antioxidant molecule found in 
the brain (Oringen and Hirrlinger, 2003). This thiol compound can act 
as an electron donor, and thus fulfils its antioxidant role either by 
directly reacting with ROS or by acting as a substrate for glutathione S-
transferase or glutathione peroxidase. Both neurons and astrocytes 
can synthesize the GSH tripeptide (L-glutamyl-Lcysteinylglycine) by 
the sequential action of glutamate cysteine ligase and glutathione 
synthetase. However, neurons are highly dependent on astrocytes for 
their own GSH synthesis. Indeed, astrocytes release GSH in the 
extracellular space, where it is processed to produce Cys-Gly that is 
then uptaken from neurons and used for the synthesis of their GSH. 
The cysteine represents the rate-limiting substrate for GSH synthesis, 
since neurons, unlike astrocytes, cannot use the cysteine-oxidation 
product cystine as a precursor (Oringen and Hirrlinger, 2003). The 
importance of this cooperative process for neuronal defence against 
oxidative stress is evidenced by the reduced ability of GSH-depleted 
astrocytes to protect neurons against oxidative injury (Chen et al., 
2001). Conversely, increasing the capacity to synthesize GSH in 
astrocytes specifically by increasing their capacity to uptake cystine 
significantly enhances the neuroprotective effect of astrocytes against 
oxidative stress (Shih et al., 2006) (Figure 1.6, green box). 
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In addition to all these fundamental functions, astrocytes have been 
found responsible for a process known as "gliotransmission" (Halassa 
et al., 2007). In brief, astrocytes detect neuronal activity as 
neurotransmitters that are released into the surroundings and respond 
to this with a transient increase in their intracellular Ca2+ levels, which 
can travel through the astrocyte syncytium in a wavelike fashion. 
These Ca2+ signals can trigger the release of neuroactive molecules 
from astrocytes (or gliotransmitters), such as glutamate, O-serine, or 
adenosine triphosphate (ATP), which in turn may modulate synaptic 
activity and neuronal excitability (Halassa et al., 2007). 
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Figure 1.6: Simplified representation of the main roles of astrocytes in brain 
homeostasis. Pink box: glutamate-glutamine cycle. Astrocytic excitatory amino 
acid transporters (EM Ts) are responsible for the uptake of a large fraction of 
glutamate at the synapse. Glutamate is converted into glutamine by glutamine 
synthetase enzyme (G8) and shuttled back to neurons for glutamate resynthesis. 
Blue boxes: Lactate shuttle. Glutamate uptake by astrocytes is accompanied by 
Na + entry, which is counteracted by the action of the Na +'K+ ATPase. The resulting 
increase in ADP/ATP ratio triggers anaerobic glucose utilization in astrocytes and 
glucose uptake from the circulation through the glucose transporter GLUT1. The 
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lactate produced is shuttled to neurons through monocarboxylate transporters 
(mainly MCT-1 in astrocytes and MCT-2 in neurons), where it can be used as an 
energy substrate after its conversion to pyruvate. Yellow box: pH buffering. 
Abundant carbonic anhydrase (CA) in astrocytes converts CO2 into H+ and HC03. 
Two HC03 are transported into the extracellular space along with one Na + via the 
Na + -HC03 cotransporter (NBC), thereby increasing the extracellular buffering 
power. Protons left in the glial compartment may drive the transport of lactate 
outside of astrocytes and into neurons through MCTs. Excess H+ in neurons is 
extruded via sodium-hydrogen exchange (NHE). Orange box: K+ buffering. 
Astrocytes buffer excess K+ released into the extracellular space as a result of 
neuronal activity. Potassium ions travel through the astrocytic syncytium down 
their concentration gradient and are released in sites of lower concentration. Green 
box: Glutathione metabolism. Astrocytes release glutathione (GSH) in the 
extracellular space where it is cleaved by the astrocytic ectoenzyme Gamma-
glutamyl transpeptidase (GGT). The resulting CysGly serves as a precursor for 
neuronal GSH synthesis. X represents an acceptor for the gamma-glutamyl moiety 
in the reaction catalyzed by GGT. Reproduced from (Belanger and Magistretti, 
2009). 
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Aims of the thesis 
Astrocytes are the most abundant cell type in the mammalian brain. 
They play crucial roles in adult CNS homeostasis and, consistently, 
their impairment is emerging as responsible for neuronal dysfunction in 
several neurodegenerative diseases (Maragakis and Rothstein, 2006). 
The aim of my thesis work was to study the role of astrocytes in the 
neurological manifestation of Multiple Sulfatase Deficiency, a severe 
lysosomal storage disorder caused by mutations in the Su/fatase 
Modifying Factor 1 (SUMF1) gene (Cosma et al., 2003). 
To achieve this aim, I had to accomplish the following tasks: 
• First, I investigated the cellular consequences of lack of Sumf1 
gene in astrocytes. I used electron microscopy and confocal 
microscopy to study in vivo and in vitro the morphology of the 
Iysosomes, the morphology and number of autophagosomes and 
the accumulation of lysosomal substrates in astrocyte lacking 
Sumf1. I took advantage of the previously generated Sumfrl -
mouse line (Settembre et al., 2007). 
• To study if lack of Sumf1 in astrocytes was contributing to the 
neurodegeneration observed in MSD, I evaluated whether 
44 
astrocytes-specific Sumf1 deletion impaired neuronal survival 
and function. I addressed this question through two different 
approaches: i) By using an ex vivo co-culture assay I studied the 
ability of Sumfrl - astrocyte to support the survival and function of 
wild-type cortical neurons; ii) Using the gene targeting in 
embryonic ES cell and the CRE/Lox techniques, I generated a 
conditional Sumf1 knockout mouse line in which Sumf1 was 
deleted in astrocyte only (Sumf1f10xlflOX; GFAP-Cre) and in both 
astrocytes and neurons (Sumf1f10xlflOX; Nestin-Cre). Then I 
evaluated cellular morphology and neurodegeneration in different 
brain regions in both mouse lines at two different ages (6 months 
and one year). 
• Third I studied the neuroinflammation in both Sumf1f1oxlflox; Nestin-
Cre and Sumf1f10xlflOX; GFAP-Cre mouse lines. I performed this 
analysis by using markers of astrocyte and microglia activation in 
brain sections. 
• Fourth, investigated whether astrocyte dysfunction is 
responsible for some of the neurological manifestation of MSD. 
To address this point I performed a thoroughly behavioural 
analysis of Sumf1f10xlflOX; Nestin-Cre and Sumf1floxlflOx; GFAP-Cre 
mouse lines. 
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Materials and Methods 
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2.1 Mice 
Sumf1 knockout mice were previously generated (Settembre et al., 
2007). The Sumf1 f10xed mouse line was generated as described in 
the Results section. The mice expressing FLP recombinase were 
purchased from Jackson Laboratories (strain 86.129S4-
Gt(ROSA)26Sorm1(FLP1)Oym/JRainJ). GFAP-Cre mice were obtained 
from National Cancer institute-Mouse Repository (strain name 86.Cg-
Tg(GFAP-cre)8Gtm). Nestin-Cre mice were purchased from Jackson 
Laboratories (strain name 86.Cg-Tg(Nes-cre)1 Kln/J). The breeding 
scheme to obtain Sumf1lloxJllox; Nestin-Cre and Sumf11l0xlllOX; GFAP-Cre 
mice was the following: 
x I ROSA-Ftp I; I Sumf1 " •. N 0/. I x I ROSA-Flp I 
! ! 
Sumf1"0>!> X Sumf1 "'. 
! 
Neslin-Cre I x I Sumf1 rto1J1Io 
! 
I x I GFAP-Cre 
! 
I Sumf1ftoX/' ; sumn- l L..-N_e_st_in_-C_re--J 
Sumf1 f1ox/fIox; 
Neslin-Cre 
Sumf1f101V110A 
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The R26-stop-EYFP mutant mice were purchased from Jackson 
laboratories (strain name B6.129X1-Gt(ROSA)26Sortm(EYFP)COS/J) and 
carried a loxP flanked stop sequence followed by the enhanced yellow 
fluorescent protein (EYFP) inserted into the ROSA26 locus. Because 
this transgenic locus was carried in homozygosity, breeding the R26-
stop-EYFP mouse with GFAP-Cre mouse was sufficient to obtain the 
ROSA-EYFP; GFAP-Cre line: 
R26-stop-
EYFP'/' GFAp·CRE I x 1 '--------' 
GFAP-CRE; 
R26-stop-EYFp·H 
Transgenic line overexpressing GFP tagged LC3 was a generous gift 
from Dr. Mizushima (Kuma and Mizushima, 2008). Here the scheme of 
the breeding with Sumf1+1- mice: 
Sumf1·/· I x I GFP-LC3'pIIg 
! 
Sumf1"'; X I 
GFP-LCJlgI> . Sumf1'" 
! 
Sumf1 -/-: 
GFP-LC3'gI< 
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Animal use and analyses were conducted in accordance with the 
guidelines of the Animal Care and Use Committee of Cardarelli 
Hospital in Naples and authorized by the Italian Ministry of Health. 
2.2 Tissue and cell culture techniques 
Astrocyte cultures were prepared from cortex isolated from 1 to 2 
postnatal day old Sumf1-I- or Sumf1+1+ pups. 
For astrocytes isolation, instruments were sterilized in 70% EtOH. The 
pup was decapitated and the head was immersed in a dish filled with 
cold dissection media (OM) - 10% glucose-bicarbonate buffer (13.33 g 
sodium bicarbonate+22.2 g glucose in SOOmL water), 1 mM sodium 
pyruvate in 1X HBSS. First, skin and skull were removed from the 
head and then the brain removed from the ventral side. Subsequently, 
olfactory bulbs were moved away from the rest of the brain, 
hemispheres were separated and meninges removed. Cortical lobes 
were isolated and transferred to a tube with 10mL of plating media -
DMEM/F12 with L-glutamine and 1SmM Hepes, supplemented with 
10% heat inactivated Horse Serum (HS), 10% Fetal Bovine Serum 
(FBS) and 1 mM sodium pyruvate. Subsequently the media was 
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aspirated and 1.5 mL of new plating media was added. The tissue was 
dissociated first using a regular Pasteur pipet, then with a flamed-tip 
Pasteur pipet with a small opening and subsequently filtered through a 
Falcon 100 micron cell strainer. One brain (both hemispheres) was 
plated on 4 four-wells 100 j..Ig/mL poly-D-Iysine coated coverslips and 
cultured in plating media changing the media every 3 days. After 2 
weeks in culture, the astrocytes were examinated by 
immunofluorescence. 
For glia-neuron co-culture, cortical neurons from wild-type mouse 
embryos at E 15.5 were isolated as follows: pregnant mouse was 
anesthetized, then the abdomen was cut and the embryos removed 
and placed in dissection media. The placenta and the yolk sac were 
removed, the heads were cut off of the body and the cortices isolated 
as described before. Neuronal cell culture was prepared similar to 
astrocytes. Finally, the neuronal preparation was plated on the top of 
Sumf1-I- or Sumfr
'
+ astrocytes and cultured for 2 weeks. To inhibit the 
proliferation of the newly added glial cells eventually contaminating the 
neuronal preparation, the cytosine arabinoside (10IJM) was added 2d 
after plating neurons. The co-culture was cultured in neuronal media-
so 
MEM supplemented with 10% glucose-bicarbonate buffer, 5% FBS, 
5% heat inactivated HS, and 1 mM sodium pyruvate. 
2.3 Methods of analysis 
2.3.1 Molecular analysis 
2.3.1.1 Genotyping 
Genotyping was performed on DNA isolated from tail biopsy at the time 
of weaning. PCR primers used were: 
For Sumf1 -/- mice 
primer 1 ,5'- CAAAGTCAGGGTCACMGGTTCAT-3' 
primer 2, 5'- AGAMCCACCTCACCAAAGCAGAG-3' 
primer 3,5'- TTTGTGCCTTTACTGCCCTCTTGG-3' 
For GFP-LC3 mice 
primer 1 ,5'-ATAACTTGCTGGCCTTTCCACT-3' 
primer 2,5'- CGGGCCATTTACCGTMGTTAT-3' 
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primer 3,5'- GCAGCTCATTGCTGTTCCTCAA-3' 
For Sumf1 flOX mice 
primer forward, 5'- TGGAGTGGGCAGGTGGAGTCAT- 3' 
primer reverse, 5'-CACAGCACGCAGGAACTGTGAG-3'. 
For FLP recombinase mice 
primer forward, 5'- CACTGATATTGTAAGTAGTTTGC-3' 
primer reverse, 5'-CTAGTGCGAAGTAGTGATCAGG-3' 
For Nestin-Cre mice 
primer forward, 5'- CGCTTCCGCTGGGTCACTGTCG-3' 
primer reverse, 5'- TCGTTGCATCGACCGGTAATGCAGGC-3' 
For GFAP-Cre mice 
primer forward, 5'- GTGTCCAA TTT ACTGACCGT ACAC-3' 
primer reverse, 5'-CTAATCGCCATCTTCCAGCAG-3' 
For R26-stop-EYFP mice 
primer 1, 5'- AAGACCGCGAAGAGTTTGTC- 3' 
primer 2, 5'-AAAGTCGCTCTGAGTTGTTAT-3' 
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primer 3,5'- GGAGCGGGAGAAATGGATATG-3' 
PCR reactions were performed using a standard protocol. 
2.3.1.2 Southern Blotting 
DNA samples were digested with Spel or Sphl. Ten micrograms of 
DNA were loaded onto 0.8 % agarose gels. After electrophoresis the 
gel was treated with O.SM NaOH, 1.SM NaCI denaturing solution for 30 
min, then 30 min in O.SM Tris-HCI, 1.SM NaCI neutralization solution. 
The gel was then equilibrated for 20 min in 20x SSC solution (3M 
NaCI, 300mM sodium citrate-2H20). DNA was transferred overnight 
onto Ni+ (Roche) membranes using capillary blotting with 20 X SSC 
buffer. The membrane was then crosslinked with 120mJ UV and 
hybridized with the respective 32P-dCTP labelled probe in Church 
buffer (0.25mM sodium phosphate buffer, 1 mM EDTA, 1 % BSA, 7% 
SOS) over night. Radioactive labelling of the probe was carried out 
using High Prime labelling kit (Roche) according to manufacturer 
instruction. After washing with 2 x SSC buffer 30 min, 1 x SSC buffer 
30 min and 0.5 x SSC buffer 10 min the hybridization signal was 
detected with BAS 2000 Biolmaging Analyser (FujiFilm). 
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2.3.1.3 Gene Expression Analysis 
Freshly dissected hemi-brains cut along the mouse brain's midline (n= 
3 mice/genotype, 6 months of age) were placed in 2 ml Trizol 
(Invitrogen) on ice and immediately homogenized with Polytron 
homogenizer. Total RNA was cleaned and DNA removed with on-
column DNase digestion using the Qiagen RNeasy Mini kit (Qiagen 
Inc). Quantitec (Qiagen) was used to synthesize first-strand cDNA from 
11lg purified total RNA. Quantitative PCR was performed using Applied 
Biosystems 7300 Real Time PCR System (Applied Biosystems). 
Quantitative PCR reactions were conducted in triplicate and the results 
were averaged for each sample and normalized to cyclophilinA levels. 
Indeed, cyclophilins are cytosolic, highly abundant proteins and 
cyclophilinA gene was used as housekeeping gene since its level was 
not changing among the different genotypes. 
RT -PCR primers used were: 
CyclophilinA_forward, 5'- GGCAMTGCTGGACCAMCACM- 3' 
Cyc/ophilinA_reverse, 5'- GTMAATGCCCGCAAGTCMAAG- 3' 
Gapdh_forward, 5'- GTCTCCTCTGACTTCMCAGCG- 3' 
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Gapdh_reverse, 5'- ACCACCCTGTTGCTGTAGCCAA- 3' 
Mip1a (CCL3}_forward, 5'- ACTGCCTGCTGCnCTCCTACA- 3' 
Mip1a (CCL3}_reverse, 5'-ATGACACCTGGCTGGGAGCAAA- 3' 
Mip1{3 (CCL4}_forward, 5'-ACCCTCCCACTTCCTGCTGTTT- 3' 
Mip1{3 (CCL4}_reverse, 5'- CTGTCTGCCTCTTTTGGTCAGG- 3' 
TNFa_forward, 5'- GGTGCCTATGTCTCAGCCTCTT- 3' 
TNFa_reverse, 5'- GCCATAGAACTGATGAGAGGGAG- 3' 
2.3.2 Biochemical analysis 
2.3.2.1 Sulfatase enzymatic assays 
Specimens were resuspended in water and then disrupted by 3 cycles 
of freeze-thaw. Then, samples were centrifuged at 13000rpm with a 
benchtop centrifuge for 15 min at 4°C and the supernatant, containing 
the protein fraction, transferred to a new tube. Protein concentration 
was measured using Bradford protein assay according manifacturers' 
instructions (Bio-Rad). For all enzyme activity assays, 30l-1g of proteins 
were incubated at 37°C for 3 hr under the specific assay conditions. 
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For ARSA assay, homogenates were incubated with 0.02M p-
nitrocatechol sulfate in 0.5M acetate buffer (pH 5) containing 0.85M 
NaGI and 0.25mM sodium pyrophosphate in an incubation volume of 
0.3ml. The reaction was stopped with 0.7ml 0.64N NaOH and 
absorbance was read at 515nm on a Perkin Elmer spectrophotometer. 
For ARSB and ARSG enzymatic activity the 4-methylumbelliferyl (4-
MU) sulfate was used as substrate. ARSB activity was determined by 
incubating cell homogenates with 6.25mM 4-MU sulfate in 0.375mM 
AgN03 0.1 M NaOAc buffer (pH 5) in 801-11 of incubation mixture. ARSG 
was measured by incubating cell homogenates with 0.2mM 4-MU 
sulfate in 0.25% Triton X100, 0.05 M phosphate buffer (pH 8) in 0.2ml 
incubation volume. For ARSB and ARSC the reactions were stopped 
with 2ml glycine-carbonate buffer pH (10.7) and fluorescence was read 
at 365nm (excitation) and 450nm (emission) on a Turner fluorometer. 
Statistical analyses of the measurements were analyzed using 
Student's t-test. Data are shown as mean ± standard error of mean. 
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2.3.3 Histological analysis 
2.3.3.1 Electron microscopy 
Mice at 3 and 6 months of age were injected intraperitoneally with 20 
mg/mL Avertin and then subjected to intracardial perfusion using PBS 
for 2 min, and then 2.5% gluteraldehyde, 2.0 % paraformaldehyde in 
0.1 M phosphate buffer for 15 min- flow rate: 10mLlmin. After perfusion, 
brain was removed, cortex isolated and cut into 1 mm cubes and 
immediately immerse in fixative solution for 2-3 hours on shaker. From 
here, preparation of samples for Electron microscopy was performed in 
collaboration with Electron microscopy Core at Baylor College of 
Medicine. 
Briefly: specimens were washed 3x 5 min each with 0.1 M phosphate 
buffer, pH7.2-7.4, post fixed for 1-2 hr in 1% Os04 in 0.1 M phosphate 
buffer, washed again 3 x 5 min each with 0.1 M phosphate buffer, then 
gradually dehydrated with increasing concentration of ETOH and 
subsequently gradually infiltrated with Spurr's resin. Finally, ultra-thin 
sections of approximately 70nm were obtained using an RMC 
MT6000-XL ultramicrotome and a Diatome Ultra45 diamond knife, and 
collected on 150 hex-mesh copper grids. The ultra-thin sections were 
then stained with Reynold's lead citrate for 4 minutes. I examined the 
57 
air-dried samples on a Hitachi H7500 transmission electron 
microscope and I captured images using Gatan US 1000 digital camera 
and Digital Micrograph v1.B2.366 software. 
I distinguished the different cell populations of the brain according 
morphological criteria (Patricia C. Cross, 1993). Briefly, glial cells were 
distinguished from neurons by their smaller, more irregular shape and 
for the prominent differences in the nucleus, devoid of nucleolus and 
with a condensed envelope. Astrocytes can be distinguished from 
other glial populations since they contain a characteristic 
intermediated-sized filament composed of glial fibrillary acidic protein 
(GFAP) and compared to oligodendrocytes are usually bigger and with 
a paler, euchromatic nucleus. Microglial cells are very similar to 
macrophages in morphology and they are the smallest cells within the 
CNS with an irregular shape and a darker cytoplasm. 
2.3.3.2 Immunofluorescence and Immunohistochemistry 
For immunofluorescent staining of mouse brain sections, mice at 3 and 
6 months of age were injected intraperitoneally with 20 mg/mL Avertin 
and then subjected to intracardial perfusion using PBS for 2 min and 
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then 4% paraformaldehyde (PFA) in PBS for 15 min- flow rate: 
10mLlmin. Brains were dissected and post-fixed with buffered 4% PFA 
overnight at 4°C, then washed with PBS and cryoprotected in 
successive sucrose solutions diluted with PBS: 5% for 30 minutes, 
10% for several hours, and 20% overnight at 4°C; finally embedded in 
OCT. Cryostat sections were cut at 30j.Jm or 50j.Jm (floating sections). 
For immunofluorescence floating sections were blocked and 
permeabilized in 3% BSA, 5% goat serum in PBS + 0.3% Triton X-100 
for 3h, then incubated with the primary antibody overnight. Sections 
were washed 3 times with 3%BSA in PBS + 0.3% Triton X-1 ~O, and 
then incubated for 3 h with secondary antibodies conjugated with 
Alexafluor 488, or Alexafluor 555, or Alexafluor 633. For 
immunofluorescence of astrocyte culture or astrocyte-neuron 
coculture, cells were washed twice in PBS then fixed with cold buffered 
4% PFA for 15' at room temperature (RT), then permeabilized with 
PBS + 0.2% Triton for 30' at RT and blocked in 3% BSA, 5% HS in 
PBS + 0.1 % Triton. The primary antibody was added overnight, 
washed with PBS and incubated with secondary antibodies. Images 
were captured using a Leica SP5 Confocal microscope and quantitave 
analysis performed using Image J software. 
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For Immunohistochemistry, after being post-fixed with buffered 4% 
PFA overnight at 4°C, brains from 6 and 12 months old mice were 
dehydrated in a graded series of ethanol: 70% ethanol for 1 hour; 95% 
ethanol for 2 hours; 100% ethanol for 2 hours; then cleared with 
Xylene for 30 minutes, 1 hour and then a further 1 hour (changing the 
solution between each time period). Finally, the specimens were 
infiltrated with paraffin for 1 hour, and then over night. Paraffin-
embedded blocks were cut on a microtome in 5 IJm sections. Sections 
were then deparaffinized in two changes of xylene followed by two 
changes of absolute ethanol, two changes of 95% ethanol, one of 70% 
and then rehydrated in tap water. Endogenous peroxidase activity was 
quenched by incubating the sections for 30 minutes in 0.3% H20 2 in 
water. Sections were then washed in PBS buffer for 5 min and 
subsequently incubated for 20 min with blocking solution (1,5 % horse 
serum in PBS). Incubation with primary antibodies (anti-Neun or anti-
calbindin) was done overnight at 4 °C in blocking solution, after which 
they were incubated with a biotinylated horse anti-mouse secondary 
antibody in PBS-1,5% horse serum. Secondary antibodies were 
visualized using avidin-biotin-horseradish peroxidase complex 
(Vectastain ABC kit, 1: 1 00 inPBS, Vector Labs, Burlingame, CA) for 30 
min followed by a PBS wash (3 x 5min), 0.05% 3,3-diaminobenzidine 
60 
tetrahydrochloride (DAB) and 0.02% H202 for 20 min, and a final PBS 
wash (3 x 5min). Bright field images were taken using a Zeiss Axioplan 
2 imaging microscope. Images were acquired with a high-resolution 
color digital camera (Axio cam) using the Zeiss AxioVision software. 
2.3.3.3 Neuronal quantification 
For the cortical neurons and Purkinje cell quantification, three sagittal 
sections/mouse (5~m thickness) starting from the median sagittal 
plane were used. Bright field images were taken using a Zeiss 
Axioplan 2 imaging microscope. Images were acquired with a high-
resolution color digital camera (Axio cam) using the Zeiss AxioVision 
software. The counts were performed using a 200 X 200 ~m grid 
throughout the section area. Five mice for genotype were used. The 
cortical layers were defined as follows: layers 11-111, 150 ~m from the 
surface to a depth of 350~m; layer IV, 350-550~m; layer V, 550-750~m 
(Hampton et al., 2010). Purkinje cells were quantified within a defined 
region of the cerebellum (VIII lobe). NeuN- and Calbindin- positive cells 
were quantified with the Imagej software analysis using the Cell 
Counter plugin with a fixed threshold. All studies were carried out with 
the observer blinded to genotype. 
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2.3.3.4 Nissl staining 
Nissl staining typically marks the ER due to ribosomal RNA, so it stains 
both neurons and glia. Briefly, 5IJm paraffin embedded sections from 6 
months old mouse brain were stained in 0.1 % cresyl violet solution for 
5 minutes, then rinsed quickly in distilled water and differentiated in 
95% ethyl alcohol for 15 minutes; finally they were cleared in xylene 
and mounted with permanent mounting media. 
2.3.3.5 Markers and Antibodies 
GFAP: standing for Glial fibrillary acidic protein, is the characteristic 
astrocyte intermediate filament, whose expression is increased during 
astrocyte activation (Brenner et al., 1994). Therefore GFAP marker is 
used to mark astrocyte cells. Antibodies used for GFAP antigen were: 
Polyclonal rabbit anti-GFAP (Dako, cat. Z0334, dilution 1 :500) and 
Monoclonal anti-GFAP antibody produced in mouse (Sigma, cat. 
G3893, dilution 1 :500). 
Ubiquitin: original name ubiquitous immunopoietic polypeptide, is a 
small polypeptide which binds to proteins for degradation, via 
proteosomal or autophagic pathway. Ubiquitin-positive aggregates 
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represent storage of poly-ubiquitinated proteins that accumulates in 
cells with impairment of autophagy (Hara et al., 2006; Komatsu et al., 
2006). The antibody used for ubiquitin antigen was: Polyclonal rabbit 
anti-Ubiquitin (Dako, cat. l0458, dilution 1 :250) 
NeuN: standing for "neuronal nuclei" is a neuron-specific nuclear 
protein, originally identified by immunoreactivity with a neuronal 
specific monoclonal antibody, anti-NeuN. It was recently identified as 
the Fox-3 gene product, whose expression is indeed specific for 
neuronal cells where it functions as a splicing regulator (Kim et al., 
2009). The antibody used for NeuN antigen was Mouse Anti-NeuN, 
clone A60 (Millipore, cat. MAB377, dilution 1 :500). 
GFP-LC3: stands for GFP-tagged LC3 protein (Kuma and Mizushima, 
2008). LC3 is an abbreviation for MAP1LC3A, the mammalian 
homologue of yeast ATG8, an important marker and effector of 
autophagy. LC3 is present in two forms in the cell, the cytosolic soluble 
LC3-1 form and the autophagosome-complexed form LC3-11. During 
autophagy, LC3-1 is lipidated becoming LC3-11 and localizes in the 
inner membrane of the rising autophagosome (phagophore) where it 
recruits autophagic substrates and is itself degradeted via autophagy. 
Therefore, accumulation of LC3-positive dots into the cells represents 
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accumulation of autophagosomes (Kabeya et al., 2000). Beacause 
LC3 was fused with GFP (green fluorescent protein) the antibody used 
for detect LC3 was Chicken polyclonal to GFP (Abcam, cat. ab92456, 
dilution1 :500). 
SQSTM11 P62: stands for Sequestosome-1 (P62 because of its 
molecular weight, 62 kDa). Similarly to LC3, P62 is both an effector 
and a substrate of autophagy: through its two binding domains, one for 
LC3 and the other for ubiquitin, it targets polyubiquitinated proteins to 
the autophagosomes for autophagy degradation. Therefore its 
intracellular accumulation often indicates impairment in autophagy 
process (Mizushima et al., 2010). The antibody used for SQSTM11 P62 
was Monoclonal Mouse anti-SQSTM1 (BD Bioscience, cat. 610833, 
dilution 1:1000) 
Calbindin: full name, Calbindin-D28k, is a calcium-binding protein 
belonging to the troponin C superfamily. In the brain, it marks Purkinje' 
cells (Whitney et al., 2008). The antibody used for calbindin was 
Monoclonal Anti-Calbindin-D-28K antibody produced in mouse (Sigma, 
CP848, dilution 1 :200). 
64 
MAP2: Microtubule-associated protein 2, is a neuron-specific protein 
that stabilizes microtubules in the dendrites of postmitotic neurons 
(Izant and Mclntosh, 1980). 
The antibody used for MAP2 was Anti-MAP2A Antibody, 28, produced 
in mouse (Millipore, cat. MA8378, dilution 1 :200). 
F4/80: F4/80 gene is the mouse homologue of the human gene EMR1 
(EGF-like module-containing mucin-like hormone receptor-like 1 ), 
which encodes a transmembrane protein present on the cell-surface of 
macrophages. Therefore, it is a marker of microglia activation (Perry et 
al., 1985). The antibody used for F4/80 was rat anti mouse F4/80 
(AbD Serotec, cat. MCA497R, dilution 1: 100). 
The secondary antibodies used were: Alexa Fluor Secondary 
Antibodies, purchased from Invitrogen and used at a dilution of 1 :500. 
2.3.4 Behavioural analysis 
All behavioural studies were carried out with the observer blinded to 
genotype. The mice were 7 months old and the number (n) used per 
genotype is noted in the corresponding figure legend. For all studies, 
the mice were allowed to habituate to the testing room for 30 minutes 
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prior to testing. 
Accelerating rotarod: Mice were placed on an accelerating rotarod 
apparatus (Ugo Basile) for 8 trials (four trials/day on two consecutive 
days) with a 60-minute rest interval between trials. Each trial lasted for 
a maximum of 5 min, during which the rod accelerated linearly from 4 
to 40 rpm. The amount of time for each mouse to fall from the rod was 
recorded for each trial. Data are shown as mean ± standard error of 
mean and analyzed with two-way ANOVA (genotype x trial) with 
repeated measures and Tukey's post hoc analysis. 
Parallel Rod Footslip Test with ANY-maze 
The parallel rod footslip test was used to assess motor incoordination 
in mice. The apparatus is adapted from Kamenset al., 2005 and was 
used in conjunction with a special version of ANY-maze to 
simultaneously assess ataxia and locomotor activity. Footslips were 
detected when a paw touched a metal plate below the parallel rod floor 
completing a circuit that was registered by the system. Locomotor 
activity was measured by the ANY-maze tracking software using an 
overhead camera. Test time was set for 10 min. Data are shown as 
mean ± standard error of mean and analyzed by one-way ANOVA with 
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Tukey's post hoc analysis. 
Open Field Assay 
The open field apparatus consisted of a clear, open Plexiglas box (40 x 
40 x 30 cm) with photo beams to record horizontal and vertical 
movements of the mouse. Overhead lighting was set at 200-lux 
illumination and a white noise generator (LafayeUe Instruments, 
Lafayette, IN) maintained a 60dB background noise. Mice were placed 
in the center of the box. Activity was quantified over a 30 minute period 
by a computer-operated Digiscan optical animal activity system 
(Accuscan Electronics, Columbus, OH). Data are shown as mean ± 
standard error of mean and analyzed by one-way ANOVA with Tukey's 
post hoc analysis. 
Light Dark Box 
The box consisted of a clear Plexiglas chamber (36 x 20 x 26 cm) with 
an open top separated from a covered black chamber (15.5 x 20 x 26 
cm) by a black partition with a small opening. Overhead lighting was 
maintained at 700lux illumination and white noise was maintained at 
60dB. Mice were placed into the illuminated side and allowed to 
explore freely for 10min. A hand-held computer (Psion Workabout mx, 
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Psion Teklogix) and the Observer program (Noldus Information 
Technologies) were used to score the mice for the number and latency 
of entries and the time spent in each compartment. Mice with all four 
feet placed into either the light or dark compartment were scored as an 
entry. Data are shown as mean ± standard error of mean and analyzed 
by one-way ANOVA with Tukey's post hoc analysis. 
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Results 
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3.1 Lysosomal storage and autophagy dysfunction in astrocytes 
of Sumf1-1- mice 
I first investigated the cellular consequences in astrocytes of global 
Sumf1-I- mice. Transmission electron microscopy revealed that 3 
months old Sumf1-I- brain cortical astrocytes presented massive 
cytoplasmic vacuolization (Figure 3.1 a) representing Iysosomes 
containing disperse and f10cullar material (arrow), and autolysosomes 
filled with partially digested cytoplasm (arrowhead), suggesting a 
defect in degradation of autophagic cargo secondary to the lysosomal 
storage. Subsequently, co-immunolabelling of astrocytes with GFAP 
and ubiquitin antibodies showed the accumulation of ubiquitin positive 
aggregates in the cytoplasm of astrocytes of Sumf1·1- mice compared 
to control (Figure 3.1 b). A similar phenotype was observed in neurons 
and microglia of Sumf1-I- mice (Figure 3.2a-c). 
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Sumf1-1-
a 
b 
Figure 3.1: Lysosomal storage and autophagy dysfunction in Sumf1-1• 
astrocytes (a) Lysosomal storage in Sumf1 -1- astrocytes. Electron micrograph 
showing large vacuoles in the cytoplasm of astrocytes of 3 months old Sumf1-1-
mice (right). Astrocytes from control mice (left) did not show signs of vacuolization . 
Enlargement shows Iysosomes containing disperse and floccular material (arrow) , 
and autolysosomes filled with partially digested cytoplasm (arrowhead). (b) 
Astrocytes from Sumf1-1- mice accumulate ubiquitin positive cytoplasmic 
aggregates. Frozen cortical tissue isolated from 3 months old Sumf1-1- and control 
mice immunostained with ubiquitin (green) and GFAP (red) antibodies. [Scale 
bars: 2 IJm (a); 10 IJm (b)] 
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Sumf1+1+ 
a 
b 
c 
Figure 3.2: Lysosomal dysfunction in Sumf1'" neurons and microglia (a) 
Lysosomal storage in Sumf1 .f- neurons. Electron micrograph showing large 
vacuoles, mainly autolysosomes filled with undigested material in the cytoplasm of 
neurons from 3 months old Sumff'- mouse (right). Control neurons (left) do not 
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show signs of vacuolization. (b) Lysosomal storage in Sumf1-I- microglia. Electron 
micrograph from cortex of 3 months old Sumf1-I- mouse shows highly vacuolized 
microglia (right). Microglia from a control mouse (left) does not show signs of 
vacuolization. (c) Accumulation of ubiquitin positive aggregates inside the 
cytoplasm of neurons. Brain tissues from 3 months old Sumf1-I- and control mice 
immunostained with ubiquitin (green) and NeuN (red) antibodies. [Scale bars: 2 IJm 
(a); 1 IJm (b); 10 IJm (c).] 
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To evaluate whether this substrate accumulation is the consequence of 
impaired autophagy (Hara et al., 2006; Komatsu et al., 2006), I isolated 
cortical astrocytes from control and Sumfrl- mice harbouring a 
transgene expressing a GFP-tagged LC3 protein (Kuma and 
Mizushima, 2008), a well-established marker for autophagosomes 
(Kabeya et al., 2000). The cytoplasm of astrocytes from Sumf1-I- mice 
had abundant accumulation of large GFP-positive auto phagosome 
vesicles (Figure 3.3a). Moreover I observed a cytoplasmic increase of 
P62ISQSTM1, a known substrate of autophagy whose accumulation 
induces cellular toxicity (Figure 3.3b) (Zatloukal et al., 2002; 8jorkoy et 
al., 2005). These data are consistent with a model in which autophagy 
is impaired rather than induced in LSD cells, suggesting that astrocytes 
from Sumf1-I - mice accumulates toxic substrates as a result of a 
lysosomal degradation defect. 
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Figure 3.3: Autophagy impairment in Sumf1,J, astrocyte . (a) Primary astrocytes 
isolated from SumfrJ-; GFP-LC3 and Sumf1+J+; GFP-LC3 pups were stained with 
GFP (green) and GFAP (red) antibodies. Histogram shows the number of GFP 
positive vesicles (representing autophagosomes) per cell. (b) Primary astrocytes 
isolated from Sumft,J- and control mice were stained with GFAP (green) and 
P62/SQSTM1 (red) antibodies. Histogram shows the quantification of P62 positive 
puncta per cell. (Astrocytes were isolated from at least three mice/genotype; at 
least 15 cells/mice were counted. Error bars represent standard deviation; * 
Student's t test P<O.05). [Scale bars : 5 IJm] 
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3.2 Generation of Sumf1f1ox mice 
The systemic nature of MSD disease precludes a complete 
understanding of the neuronal dysfunction per se by using Sumf1 
global KO. To overcome this issue, I generated a transgenic mouse 
line carrying a conditional null mutation in the Sumf1 gene (Sumf1 f1ox 
mice). I used the gene targeting strategy to insert 10xP sites on either 
side of exon 4 (Figure 3.4a, green arrows). Indeed, Cre-mediated 
excision of exon 4 is predicted to cause a frameshift mutation and the 
incorporation of multiple stop codons. The conditional targeting vector 
for Sumf1 gene was constructed using a BAC containing the C57BLl6J 
Sumf1 genomic clone. A fragment spanning from intron 3 to intron 6 of 
Sumf1 was subcloned into PL253 (a pBluescript derived plasmid) via 
recombineering (Copeland et al., 2001) using EL350 bacteria cells (a 
derived strain of DH10B cells, carrying the temperature inducible Red 
genes). Subsequently the 10xP site upstream the exon 4 was cloned 
into the plasmid by introducing a floxed neomycin resistance (Neo) 
cassette (amplified from PL452 plasmid) via homologous 
recombination. Then the resistance cassette was removed via Cre 
recombinase, leaving a single loxP site at the targeted locus. The 
insertion of the second loxP site was accomplished using a neomycin 
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cassette flanked with two FRT sites (Figure 3.4a, black arrows) and 
one loxP site following the second FRT (amplified from PL451 
plasmid); the Sumf1 targeting vector was linearized with Notl and 
electroporated into Bruce4 mouse embryonic stem cells, and the 
G418-resistant clones were screened by Southern Blot using the 
strategy shown in Figure 3.4a. Euploid clones that had undergone 
homologous recombination were injected into albino C57BL6/J 
blastocysts. Germline transmission of the f10xed allele in offspring was 
confirmed by Southern blot (Figure 3.4b). To remove the Neo cassette, 
the resulting mice were crossed with mice expressing FLP 
recombinase. 
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Figure 3.4: Generation of the conditional knockout (eKO) Sumf1 mouse line 
(a) Schematic representation of the homologous recombination event between the 
Sumf1 targeting vector and the Sumf1 genomic locus. Correctly targeted ES cells 
(CKO allele) have a 8.3kb Spel band, in addition to a 10kb wild-type band, 
following hybridization with the 5' probe. These CKO clones also have a 8.4kb 
Sphl-targeted band, as well as a 12kb wild-type band following hybridization with 
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the 3' probe. (b) Germ-line transmission of the CKO allele. Genomic DNA derived 
from 21 pups was digested with Spel and the Southern blot analyzed using a 5' 
probe; a total of 8 germ-line mice were found (asterisks). (c) peR genotyping of 
Sumf1flox mice. Top panel: Schematic representation of primers used. Bottom 
panel: PCR products visualized by agarose gel electrophoresis. Band sizes were 
180 bp for the wild-type allele and 250 bp for the targeted allele. 
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3.3 Deletion of Sumf1 gene in neuronal precursor derived cells or 
in astrocytes 
To analyze neuronal dysfunction in MSD and dissect the contribute of 
astrocyte impairment, I generated two mouse lines: one in which 
Sumf1 was deleted in neuronal precursor derived cells (NPCs -both 
neurons and glia) which was obtained by crossing a transgenic mouse 
that expresses the Cre recombinase under the control of the nestin 
promoter with the Sumf1f1oxlflox mouse (Sumf1f10xlflOX; Nestin-Cre) and 
the other in which Sumf1 was deleted only in astrocytes, obtained 
using a transgenic mouse expressing the Cre recombinase under the 
control of the GFAP promoter (Sumf1f10xlflox; GFAP-Cre). I selected a 
GFAP-Cre line that was recently shown to be astrocyte specific 
(Weidemann et al., 2009). I first verified that this transgenic line is 
indeed specific for astrocytes by crossing it with a ROSA26-EYFP 
reporter mouse line and I observed that the YFP colocalized with the 
astrocyte marker GFAP, but not with the neuronal marker NeuN 
(Figure 3.5a-c). 
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Figure 3.5: Specificity of GFAP-Cre transgenic line. (a,b) YFP protein 
colocalizes with the GFAP marker for astrocytes and not with the neuronal marker 
NeuN in GFAP-Cre+; Rosa-YFP +/. mouse. Immunostaining using GFP antibody 
(green), GFAP-antibody (red) and NeuN-antibody (grey) from cortex (a) and 
hippocampus (b). (c) Colocalization of YFP protein (green) with GFAP marker (red) 
in the Bergmann gl ia of cerebellum in GFAP-Cre+; Rosa-YFP +/- mouse. [Scale 
bars: 20 ~m] 
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Primary glial cultures isolated from Sumf1floxlflox; GFAP-Cre mice 
showed an almost complete lack of Sumf1 mRNA expression (Figure 
3.6a) and virtually no residual sulfatase activities (Figure 3.6b), 
whereas primary cortical neurons from the same mice had normal 
levels of Sumf1 mRNA and normal sulfatase activities (Figure 3.6a,b). 
Ultrastructural analysis of brain slices isolated from 6 months old 
Sumf1flOxlflOX; GFAP-Cre mice showed neurons with normal cytoplasm 
in close proximity to astrocytes with enlarged vacuoles containing 
floccular material, which are typical signs of lysosomal storage (Figure 
3.6c). 
In Sumf1flOxlflOX; Nestin-Cre both the expression levels of Sumf1 and the 
activities of sulfatases were almost undetectable in whole brain Iysates 
(Figure 3.6d,e). Accordingly, at 6 months of age, the cytoplasm of 
neurons and astrocytes had extensive vacuolization, representing 
enlarged Iysosomes and autolysosomes containing undigested 
material (Figure 3.6f). 
Sumf1flOxlflOX; Nestin-Cre and Sumf1f10xlflOX; GFAP-Cre mice were born at 
Mendelian ratios, and indistinguishable in appearance from control 
littermates. However, I observed significant weight loss in Sumf1f1oxlflox; 
Nestin-Cre starting from 3 months of age and even more evident at 6 
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months of age (Figure 3.7a), whereas no difference in body weight was 
observed in Sumf1f10xlflOX; GFAP-Cre mice compared to their control 
littermates. Both genotypes showed signs of neurodegeneration as 
early as 6 months of age, including abnormal limb-clasping reflexes 
(Figure 3.7b), tremor, and epileptic episodes. Behavioral abnormalities 
were also assessed at 7 months of age (as described in section 3.7). 
The onset of symptoms for the two mouse lines is reported in Table 
3.1. 
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Figure 3.6: Lysosomal storage in Sumf1fIO:xJfIOX; GFAP-CRE and Sumf1f'o:xJf'ox; 
Nestin-Cre mouse lines (a) Lack of Sumf1 expression in Sumf1floXlflox,- GFAP-Cre 
astrocytes. Reverse transcription followed by quantitative PCR (RT-qPCR) of 
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Sumf1 gene expression in astrocyte (full bars) and neurons (dashed bars) isolated 
from Sumf1floxlflox (grey) and Sumf1f10xlflOX; GFAP-Cre (orange). (b) Lack of sulfatase 
activities in Sumf1 f1ox!f1oX; GFAP-Cre astrocytes. The enzymatic activities of ArsA, 
ArsB and ArsC sulfatases were measured in astrocytes (full bars) and neurons 
(dashed bars) isolated from Sumf1f10xlflox (grey) and Sumf1f10xlflOX; GFAP-Cre 
(orange). (c) Lysosomal storage in Sumf1f1oxlflox; GFAP-Cre astrocytes. (left) 
Electron micrograph of cortical tissue isolated from Sumf1f10xlflox; GFAP-Cre at 6 
months of age showing healthy neurons (arrows) in proximity to a vacuolized 
astrocyte (arrowhead). (right) Enlargement of the boxed area in left showing 
floccular materials inside vacuoles. (d) Lack of Sumf1 expression in Sumf1f1oxlflox; 
Nestin-Cre brain. RT-qPCR of Sumf1 gene was performed in whole brain 
homogenates (full bars) and, as control, in liver homogenates (dashed bars) from 
Sumf1floxlflox (grey bar) and Sumf1flOxlflOX; Nestin-Cre (purple bar). (e) Lack of 
sulfatase activities in Sumf1f1oxlflox; Nestin-Cre brain. Enzymatic activities of ArsA, 
ArsB and ArsC sulfatases were measured in whole brain homogenates (full bars) 
and liver homogenates (dashed bars) from Sumf1f1oxlflOx (grey) and Sumf1f1oxlflOx; 
Nestin-Cre (purple). (f) Lysosomal storage in both neurons and astrocytes in 
Sumf1#10xlflOX; Nestin-Cre mouse. Electron micrograph of Sumf1 flOx!flOx; Nestin-Cre 
mouse at 6 months of age showing vacuolization of a neuron (left panel) and an 
astrocyte (right panel). Enlargements show details of the undigested material 
contained in the vacuoles. All enzymatic activities are indicated as percentage of 
activity relative to the control genotype (values represent means of n=3 
mice/genotype. *, Student's t test P<O.05, **, Student's t test P<O.01). [Scale bars: 
2 lJm (c, f).] 
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Figure 3.7: Sumf1f1oxlflox; Nestin-Cre and Sumf1f1oxlflox; GFAP-Cre mouse 
phenotypes (a) Weight loss in Sumf1flOxJflOX; Nestin-Cre. Mean weight values of 
mice with indicated genotypes at 6 months of age. (Values represent means of 
n=10 mice for each group. *, Student's t test P<O.05). (b) Abnormal limb-clasping 
reflexes in both Sumf1flOxlflOX; Nestin-Cre and Sumf1flOxlflox; GFAP-Cre mice at 6 
months of age. 
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Viability 
Reduced body 
weight 
Hindlimb 
clasping 
Tremor/epileptic 
episodes 
Behavioral 
abnormalities 
Sumf1noxinox: 
Nestin·Cre 
> 14 months 
3 months 
6 months 
6 months 
7 months 
Sumf1f1oxlflox; 
GFAP-Cre 
> 14 months 
none 
6 months 
6 months 
7 months 
Table 3.1: Summary of the symptoms onset for Sumf1floxlflox; Nestin-Cre and 
Sumf1"OxlfloX; GFAP·Cre mice. 
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3.4 Lysosomal storage in astrocytes causes degeneration of 
cortical neurons in vivo 
Regional neurodegeneration was qualitatively evaluated using Nissl 
staining in sagittal brain sections isolated from Sumf1flOxlflOX; Nestin-Cre, 
Sumf1flOxlflOX; GFAP-Cre and control mice at 6 months of age (Figure 
3.8a). I observed a decreased cellular density in cortical regions in 
both Sumf1flOxJflOX; Nestin-Cre and Sumf1flOx/flOX; GFAP-Cre mice 
compared to controls. To perform a quantitative analysis, I undertook a 
grid-based neuronal count analysis on cortical slices using NeuN 
immunostaining. At 6 months of age I observed a significant decrease 
in the number of cortical neurons in Sumf1floxlflox; Nestin-Cre compared 
to control neurons in all the examined layers of the cortex (11 to V) 
(Figure 3.8b,c). Surprisingly, a decreased neuronal number was also 
observed in the cortex of Sumf1flOxlflOX; GFAP-Cre compared to control 
mice (Figure 3.8b,c). Interestingly, in Sumf1flOxlflOX; GFAP-Cre this 
decrease was evident in the more superficial layers (11, III and IV), 
whereas no significant changes were observed in deeper cortical 
layers. This phenotype was even more pronounced in 12 month old 
mice, suggesting a progressive neuronal cell loss (Figure 3.9a,c). 
These observations suggest that lysosomal storage in cortical 
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astrocytes is sufficient to trigger degeneration of cortical neurons. I 
then analyzed Purkinje cells of the cerebellum, as their degeneration is 
documented in several LSDs (Fischer et al., 1998; Ellinwood et al., 
2003; Sleat et al., 2004; Ko et al., 2005; Settembre et al., 2007). 
Calbindin staining showed a dramatic Purkinje cell loss in Sumf1f10xlflOX; 
Nestin-Cre mice, whereas no significant differences were found in 
Sumf1f10xlflOX; GFAP-Cre mice even at 12 months of age (Figure 3.9b, 
quantification in d), even though there was expression of Cre in the 
Bergmann glia of these mice (see Figure 3.5c). These data indicated 
that Purkinje cell degeneration is likely to be cell-autonomous. 
Interestingly, in younger Sumf1flOxJflOX; Nestin-Cre mice (3 months of 
age) I observed massive lysosomal vacuolization in Purkinje cells, 
whereas cortical neurons appear to be less affected (Figure 3.10). 
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Figure 3.8: Cellular loss in brain cortex of Sumf1f1oxJflox; GFAP-Cre and 
Sumf1f1oxJflox; Nestin-Cre mice. a) Nissl staining of brain slices was performed in 
control (Sumf1f1oxfflOX) mice, Sumf1fiOxfflOX; GFAP-Cre mice and Sumf1 floxfflox; Nestin-
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Cre mice at 6 months of age. Different areas of the cortex are shown from each 
genotype. [Scale bars: 200 IJm]. b) NeuN immunostaining (brown) of frontal cortex 
of mice with the indicated genotype at 6 months of age. Dashed lines mark the 
different cortical layers. c) Quantification of cortical neuron in Sumf1f10xlflox; Nestin-
Cre and Sumf1f10xlflOX; GFAP-Cre mice relative to control. The graph represents the 
means expressed as percentage relative to control (three slices were counted for 
mice; n=5 mice for each genotype .• , Student's t test P<0.05). [Scale bars: 200 IJm] 
91 
a 
IV 
V 
Sum!l'" 
b 
c UO 
:;-100 
C 10 
.., c 
!;60 
#- ~ 40 
! 20 
0 
11-111 IV V 
Sum!l' 
GFAP-Cr~ 
Sumjl - ; 
Sum!1 
• Sum!l _ ... ; GFAP<re 
• SumfJ ; N .. .",-Cn 
d lZ0 
Sum!l """ ; 
Nestin-C r~ 
.. .. 
. ... ~ . f 
' .. 
Sum!l' 
. 
. ;: . . r, .' 
~100 I 
~ C 80 _ c 
.. - 60 ~ l40 
~ 20 
o 
Figure 3.9: Lysosomal storage in astrocytes induces cortical neuronal 
degeneration. (a) Cortical neuronal loss in Sumf1f10xlflox. . Nestin-Cre and 
Sumf1flOxlflOX; GFAP-Cre mice. (a) NeuN immunostaining (brown) of frontal cortex of 
mice with the indicated genotype at 12 months of age. Dashed lines mark the 
different cortical layers. Boxed areas are enlarged below. (b) Purkinje cell 
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degeneration in Sumf1f10xlflOx; Nestin-Cre mice. Calbindin immunostaining (brown) 
of Purkinje cells in cerebellar sections obtained from 12 months old mice with 
indicated genotypes. Boxed area represent an enlargement showing a detail of the 
Purkinje cell layer. (c,d) Quantification of cortical neuron (c) and of Purkinje cells 
(d) in Sumf1floxlflOX; Nestin-Cre and Sumf1flOxlflox; GFAP-Cre mice relative to control. 
The graphs represent the means expressed as percentage relative to control 
(three slices were counted for mice; n=5 mice for each genotype. *, Student's t test 
P<0.05). [Scale bars: 200 ~m] 
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Figure 3.10: Lysosomal storage in cortical neurons and Purkinje cells in 3 
months old mice. Electron micrographs showing lysosomal storage in Purkinje 
cells (top) and cortical neurons (bottom) in Sumf1flOxlflOx; Nestin-Cre (right), in 
Sumf1f1oxlflOX; GFAP-Cre (center) and in control (left). Vacuoles (arrows) are present 
only in neurons from Sumf1f1oxlf1ox; Nestin-Cre and the ones in cortical neurons 
appear fewer and much smaller compared to the ones observed in the Purkinje 
cells from the same mouse. [Scale bars: 2 IJm] 
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3.5 Lysosomal storage in astrocytes impairs their ability to 
support cortical neuron survival 
To confirm that lack of Sumf1 in astrocytes can trigger death of cortical 
neurons, I co-cultured cortical neurons onto a layer of astrocytes. Wild 
type cortical neurons isolated from embryos at E15.5 were plated at 
similar densities on a layer of cortical astrocytes isolated from either 
wild type or Sumf1-I- newborn mice. After 12 days of culture, the 
neurons plated on wild type astrocytes formed extensive neuronal 
networks, whereas the neurons plated on Sumf1-I- astrocytes were 
significantly fewer (63%±8 vs ctrl) and appeared less branched (Figure 
3.11a). 
Excitotoxicity is the pathological process by which neurons are 
damaged and killed by excessive stimulation by neurotransmiUers 
such as glutamate. Under normal physiological condition, 
neurotransmitters stimulation is accompanied by the opening of 
voltage dependent Ca2+ channels (VDCC), which cause a small rise in 
intracellular calcium that can be buffered in the cell. However, 
neurotransmitters overstimulation induces high calcium conductivity, 
resulting in high Ca2+ loads and, ultimately, mitochondrial damage, 
apoptosis and cell death (Jaiswal et al., 2009). 
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As described in Introduction section (1.9.2), astrocytes are deputed to 
the uptake of glutamate from the neuronal synapses to avoid 
excessive neuronal stimulation, hence excitotoxicity. Therefore, to 
evaluate if Sumf1-I- astrocytes were able to protect neurons from 
excitotoxicity, I challenge neurons with glutamate (0.1 mM for 24 
hours). This treatment further decreased the survival of the neurons 
co-cultured with Sumf1-I- astrocytes compared to wild type astrocytes 
(33%±6 when plated on Sumf1-'- glia vs 65%±10 when plated on wild 
type glia) (Figure 3.11 b). A similar difference was obtained after 
stimulation with a higher dose of glutamate (0.2mM) (13%±3 when 
plated on Sumfr'- glia vs 28%±5 when plated on wild type glia) (Figure 
3.11 c). To assess whether this effect was indeed specific of an 
impairment of astrocyte function, I treated the two co-cultures with N-
methyl-D-aspartate (NMDA) (0.1 mM), which causes neuronal toxicity 
independently of astrocytes. Indeed, NMDA is a selective agonist for 
the NMDA receptors that specifically localized on neurons. In this 
case, treatment with NMDA resulted in comparable cell death (60%±B 
when plated on Sumfr'- glia vs 56%±7 when plated on wild type glia). 
(Figure 3.11 d). Together these data indicate that lysosomal storage 
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impairs the ability of astrocytes to provide support and protection to 
cortical neurons. 
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Figure 3.11: Lysosomal storage in astrocytes induces cortical neuron 
degeneration in an ex vivo co-culture assay (a-d) MAP2 (green) and GFAP 
(red) immunostaining of neurons and astrocytes after 12 days in culture. (a) not 
stimulated; (b) stimulated with glutamate 0.1 mM; (c) stimulated with glutamate 
0.2mM; (d) stimulated with NMDA 0.1 mM. (e) Histogram represents quantification 
of MAP2-positive wild type neurons plated on SumWI. glia and left untreated. 
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Values are expressed as % relative to MAP2-positive wild type neurons plated on 
Sumf1+1+ glia. (f) Histogram represents quantification of MAP-2 positive neurons 
plated on Sumf1+1+ glia or on Sumfrl - glia and stimulated as indicated for 24h. 
Values are represented as decrease (%) relative to the same sample before the 
stimulation. The data (mean ±SEM) were obtained from 3 independent co-culture 
experiments *, Student's t test P<0.05. [Scale bars: 20 IJm] 
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3.6 Lysosomal storage in neurons elicits neuroinflammation in 
MSD. 
Neuroinflammation is implicated in the progressive nature of several 
neurodegenerative diseases, and it is described in almost all LSDs 
with neurological involvement (Wada et al., 2000; Wu et al., 2000; 
Jeyakumar et al., 2003; Ohmi et al., 2003; Kielar et al., 2007; 
Settembre et al., 2007; Farfel-Becker et al., 2011). However, it is still 
unclear whether macrophage and astrocyte activation in LSDs is 
triggered by their own intracellular storage, or if it represents a 
response to neuronal damage. To address this, I examined 
neuroinflammation in my mouse models through F4/80 immunostaing. 
I observed strong microglial activation in different brain regions of 
Sumf1flOxJflOX; Nestin-Cre mice (Figure 3.12a,b), although in this model 
the microglia were not subjected to the CRE-mediated Sumf1 deletion. 
I did not observe any microglia activation in Sumf1flOxlflOX; GFAP-Cre, 
suggesting that direct neuronal dysfunction triggers microglia 
activation. Similarly, Sumf1flOxlflOX; Nestin-Cre presented severe signs 
of astroglyosis whereas the Sumf1flOxJflOX; GFAP-Cre did not (Figure 
3.12c,d), although in both models astrocytes presented lysosomal 
vacuolization. Furthermore, the mRNA levels of the chemokines Mip1a 
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and Mip1 f3 and of the cytokine TNFa were significantly upregulated in 
Sumf1flOxlflOX; Nestin-Cre mice but not in Sumf1flOxlflOX; GFAP-Cre mice 
compared to control mice (Figure 3.12e). These observations clearly 
indicate that lysosomal storage in neurons, rather than in astrocytes or 
microglia, triggers neuroinflammation in LSDs. 
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Figure 3.12: Neuroinflammation in Sumf1f1oxJflox; Nestin-Cre but not in 
Sumf1f1oxJflox; GFAP-Cre mouse brain. (a ,b) F4/80 immunostaining in cortical (a) 
and cerebellar (b) sections isolated from 6 months old mice with indicated 
genotype. (c,d) GFAP immunostaining of cortical (c) and cerebellar (d) sections 
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from the same mice. (e) RT-qPCR of Mip1a and Mip1b chemokines and TNFa 
cytokine in Sumf1f10xlflOX, Sumf1f10xlflOX; GFAP-Cre and Sumf1f10xlflOx; Nestin-Cre brain 
extracts at 6 months of age (values represent means of n=3 mice for each group. 
*, Student's t test P<0.05). [Scale bars: 200 IJm (a-d).] 
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3.7 Astrocyte dysfunction contributes to MSD behavioural 
abnormalities 
To study the neurological phenotype in MSD without the influence of 
peripheral organ dysfunction and to understand the contribution of 
astrocytes, I performed a panel of behavioural tests in both 
Sumf1flOxlflOX; Nestin-Cre and Sumf1flOxlflOx; GFAP-Cre and their 
littermate controls. At 7 months of age, mice from both genotypes 
showed a statistically significant impairment in motor performance as 
assessed by decreased latency to fall in the rotarod test and increased 
number of footfalls in the parallel-rod test (Figure 3.13a,b). However, 
Sumf1flOx!flOX; Nestin-Cre mice were unable to improve their 
performance on the rota rod after several trials, whereas the 
Sumf1floxlflox; GFAP-Cre mice showed signs of improvement (Figure 
3.13a). The Sumf1flOxlflOX; Nestin-Cre also presented a specific 
hyperactive behaviour as demonstrated by both Open Field and 
LighUDark tests (Figure 3.13c-h) whereas the Sumf1flOxlflOX; GFAP-Cre 
mice were significantly hypoactive and more anxious compared with 
control mice since they spent less time in the light and had a reduced 
number of transits in lighUdark test and horizontal beam breaks (Figure 
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3.13g-i). The behavioural phenotype observed in Sumf1f10xlflOX; Nestin-
Cre and in Sumf1ftOxlflOX; GFAP-Cre mice are summarized in Table 3.2. 
Therefore, although concomitant storage in neurons and glia causes a 
more severe phenotype, the lysosomal dysfunction in astrocytes only 
is sufficient to cause neurological impairment. 
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Figure 3.13: Astrocyte dysfunction contributes to MSD neurological 
impairment (a) Rotarod Test: Sumf1 floxlflox; Nestin-Cre and Sumf1"Oxlflox; GFAP-
Cre mice showed decreased latency to fall . (b) Parallel rod test: Increased number 
of footfa lls for both Sumf1flOxlflox; Nestin-Cre and Sumf1floxlflox; GFAP-Cre mice. (c-f) 
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Hyperactive behavior of Sumf1f10xlflOX; Nestin-Cre mice as assessed in Open Field 
Assay. (c) Increased total distance travelled, (d) increased time spent in 
movement, (e) increased ratio of the distance travelled in the center with respect 
the total distance travelled, (f) increased vertical activity in Sumf1f10xlflOX; Nestin-Cre 
mice. (g-i) Hypoactive behaviour of Sumf1f1oxlflOx; GFAP-Cre mice. (g) Decreased 
time spent in the light in Sumf1f1ox!flox; GFAP-Cre mice as assessed by Light/Dark 
test. On the contrary, Sumf1f10xlflOX; Nestin-Cre mice spent more time in the light 
side. (h) Similar results were observed by measuring the number of transits 
between the two sides of the light-dark box. (i) Decreased number of horizontal 
beam breaks in Sumf1f10xlflOX; GFAP-Cre mice as assessed in Open Field. 
The number of mice used for each genotype was: n=9 Sumf1f1oxlflox ; n=8 
Sumf1f1oxl+; Nestin-Cre; n=8 Sumf1f10xl+; GFAP-Cre; n=10 Sumf1f10xlflOx; Nestin-Cre; 
n=10 Sumf1f10xlflOX; GFAP-Cre. The control genotypes used for Sumf1f10xlflOx; Nestin-
Cre mouse were Sumf1f1oxlflox and Sumf1flOxl+; Nestin-Cre, whereas for Sumf1flOxlflOx; 
GFAP-Cre mouse were Sumf1f1oxlflox and Sumf1flOxl+; GFAP-Cre mouse. *, P S 0.05; 
** P:s 0.01; *** P:s 0.001. ns, not significant. Values represent mean ±SEM. 
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Neurological 
features 
Hyperactivity 
Altered weight 
Hindlimb 
clasping 
Motor 
incoordination 
Motor learning 
Hypoactivity 
Anxiety 
Sumf1f1oxm01; 
Nestin-Cre 
x 
x 
x 
x 
x 
Sumf1noxlflox ; 
GFAP·Cre 
x 
)( 
)( 
x 
Table 3.2: Summary of the neurolog ical features found in Sumf1floxlf10X; 
Nestin-Cre and Sumf1floxlflox; GFAP·Cre mice. Comparison between the data 
obtained from the analysis of the two mouse models shows distinct behavioural 
phenotypes. "X" indicates the presence of the alterations in the specific LSD 
neurological feature . 
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Discussion 
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Astrocytes are the main neural cell type responsible for the 
maintenance of brain homeostasis. Their processes form extensive 
networks, which modulate neuronal activity through the expression of 
various receptors for neurotransmitters, several transporters, cytokines 
and growth factors. Indeed, they play critical roles in neurotransmitter 
trafficking and recycling, nutrient and ion metabolism, and protect 
against oxidative stress (Belanger and Magistretti, 2009). Consistent 
with such a variety of fundamental functions exerted by astrocytes to 
support neurons, astrocyte impairment has been found to contribute to 
neuronal dysfunction in several neurodegenerative diseases. 
In Amyotrophic lateral sclerosis (ALS), deletion of the mutant form of 
superoxide dismutase in astrocytes only, delayed microglial activation 
and sharply slowed later disease progression of the mouse model of 
ALS (Yamanaka et al., 2008). 
Moreover, reactive astrocytes are observed in close association with 
A~ plaques in the brains of Alzheimer disease patients (Nagele et al., 
2004) and have been shown to be capable of internalizing and 
degrading A~ peptides (Nagele et al., 2003). Consistently, when 
exogenous astrocytes were transplanted into the brain of A~ plaque-
bearing transgenic mice, they migrated towards A~ deposits and 
internalized A~-positive material (Pihlaja et al., 2008). 
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Furthermore, a mouse model of Huntington disease expressing the 
mutant form of huntingtin in astrocytes only, presented an age-
dependent neurological phenotype: body weight loss, motor function 
deficits, and untimely death (Bradford et al., 2009). Finally, it was 
recently shown that in a mouse model of Rett's syndrome, re-
expression of the depleted gene (MECP2) in astrocytes only, 
significantly improved locomotion and anxiety levels, restored neuronal 
abnormalities, restored respiratory abnormalities to a normal pattern, 
and greatly prolonged lifespan compared control mice (Lioy et al., 
2011 ). 
The contribution of astrocyte impairment to neuronal dysfunction in 
human degenerative diseases could actually be even more important 
than can be addressed using mouse models. There has been a 
dramatic increase in the number and complexity of astroglia during the 
course of evolution: a steady increase of the astrocyte-to-neuron ratio, 
going from about 1/6 in nematodes to 1/3 in rodents, and reaching up 
to 1.65 astrocytes per neuron in the human cortex (Sherwood et al., 
2006). Importantly, more than simply outnumbering their rodent 
counterparts, human astrocytes are also strikingly more complex, both 
morphologically and functionally. In comparison, human neocortical 
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astrocytes are 2.5 times larger, extend 10 times more processes, and 
display unique microanatomical features. In addition, they generate 
more robust intracellular Ca2+ responses to neurotransmitter receptor 
agonists and display a 4-fold increase in Ca2+ wave velocity (Oberheim 
et al., 2009). This points to a role for astrocytes in the evolution of 
uniquely human traits such as cognition and further suggests that 
astrocytes likely play roles in neurological diseases. 
Neurodegeneration is one of the most common and prominent features 
in LSDs. Neuropathological symptoms include developmental delay, 
abnormal ocular movements, ataxia, seizures, movement disorders, 
spasticity, visual loss and psychiatric disease (psychosis, depression 
and dementia)(Platt FM, 2004). However, very little is known about the 
role of astrocytes in LSDs neuropathogenesis. 
During my PhD I studied a severe type of LSD known as Multiple 
Sulfatase Deficiency. To analyze the contribution of astrocytes to the 
neurological phenotype of MSD, I generated a conditional knockout 
mouse line of the Sumf1 gene and crossed it with a transgenic mouse 
line expressing the ere recombinase gene under the control of GFAP 
promoter, to delete Sumf1 only in astrocytes. I observed that removing 
Sumf1 in astrocytes caused lysosomal/autophagic dysfunction and in 
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turn led to the accumulation of toxic substrates in their cytoplasm. 
Based on my results, I cannot conclude at which steps the lysosomal 
storage impairs the autophagic process. However, the presence of 
large autolysosomes in the cytoplasm of Sumf1-I- astrocytes supports a 
model in which the autophagic block occurs at level of intralysosomal 
degradation of autophagic substrates. Further studies will be required 
to address more in detail this aspect. 
I found both in vivo and in vitro that astrocytes deprived of Sumf1 gene 
directly contributed to neurodegeneration since they lost their ability to 
support neuronal survival and function. This supportive function 
appeared to be particularly important for cortical neuron survival, 
although I cannot formally exclude that also other neuronal populations 
were affected in Sumf1floxlflox; GFAP-Cre mice. 
Recent studies performed on a model of LSD, Niemann-Pick type C 
disease, showed that selective deletion of Npc1 gene only in 
astrocytes did not induce neurodegeneration, and indeed this disease 
is largely caused by a cell-autonomous Purkinje cell degeneration 
(Elrick et al., 2010; Yu et al., 2011). Consistent with this observation, I 
found that while lysosomal dysfunction in astrocytes may represent a 
significant determinant for cortical neuronal degeneration, a cell 
autonomous pathway accounted for Purkinje cell death, since these 
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neurons only degenerated in the Sumf1f10xJflox; Nestin-Cre mice. In 
support of this model, in 3 months old Sumf1f1oxJflox; Nestin-Cre mice I 
observed a massive lysosomal vacuolization in Purkinje cells whereas 
it was barely detectable in cortical neurons (Figure 3.10). This 
difference may be due to a higher glycosaminoglycan metabolism in 
Purkinje cells compared to cortical neurons. Together these data 
indicated that, in LSDs, neurodegeneration involves both cell 
autonomous and non-autonomous pathways. 
Lysosomal enzymes are either targeted to the lysosome or secreted in 
a mannose-6-phosphate receptor dependent fashion (Ni et al., 2006). 
Secreted enzymes can be taken up by the surrounding cells or even by 
distant cells through the circulation. This secretion/uptake mechanism 
most likely account for the milder cellular phenotype observed in 
Sumf1f1oxJflox; Nestin-Cre compared to the one found in Sumf1-/· mice 
(compare vacuolization in Figure 3.6f with the one observed in Figure 
3.2a). In Sumf1f1ox/flox; Nestin-Cre sulfatases may be secreted by non-
recombined cells such as microglia and blood vessel cells and taken 
up by neurons and astrocytes. However, my data indicate that uptake 
of enzymes from healthy cell types is not able to compensate for the 
genetic defect. Indeed, even if for some LSDs hematopoietic stem cell 
transplantation (HSCT) has demonstrated some efficacy proving that 
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donor-derived macrophages and microglia can progressively become a 
stable source of endogenous enzyme in the central nervous system, 
for many others this approach has been unsatisfactory (Orchard et al., 
2007). Currently, new promising therapies combine gene therapy and 
HSCT to obtain hematopoietic donor cells that express supra-
physiological levels of the absent enzyme resulting in increased levels 
of enzyme secretion (Biffi et al., 2004). 
Considering that astrocytes make up as much as 50% of the brain's 
volume (Benarroch, 2005), the observation that astrocyte dysfunction 
Significantly contributes to neurodegeneration in MSD may suggest 
also a new alternative therapeutic approach for the treatment of 
neurological impairment in LSDs. 
In the recent years neural precursor cell (NPC) transplantation has 
been described as a strategy for slowing neurodegenerative disease 
progression because engrafted cells have the potential of replacing 
lost or dysfunctional neurons and glia. However, this is a challenging 
strategy for neurodegenerative diseases because of problems related 
to neuronal differentiation and to the establishment of appropriate 
circuitry with host neurons (Le Belle and Svendsen, 2002). In addition 
to NPCs, there is an increasing literature that implicates a direct glial 
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cell-mediated neuroprotective effect in models of acute and 
progressive neuronal injury through modification of a hostile 
endogenous astroglial environment in the context of noncell-
autonomous neurodegeneration. Transplantation of glia-restricted 
precursors extended survival and disease duration, attenuated motor 
neuron loss, and slowed declines in fore-limb motor and respiratory 
physiological function in a rat model of ALS (Lepore et al., 2008). 
Moreover, direct astrocyte implantation reduced cortical neuron 
degeneration in a transgenic mouse of a tauopathy (Hampton et aI., 
2010). Similarly, this approach could represent an intriguing 
therapeutic strategy to treat some aspects of the neurological 
manifestation of LSDs. 
Because in LSDs with neurological involvement all the cell types of the 
brain are affected by the lysosomal storage, the activation of the 
inflammatory system could be either the consequence of the 
intracellular storage in astrocytes and microglia or the secondary effect 
of neuronal damage. Neuroinflammation has been proposed to induce 
oxidative stress, excitotoxicity and metabolic failure in 
neurodegenerative diseases. In this scenario the suffering reactive 
astrocytes and microglia would exacerbate neuronal deterioration at a 
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later stage of disease progression (Allan and Rothwell, 2003; 
Sofroniew, 2005; Farina et al., 2007). I observed signs of 
neuroinflammation characterized by microglial activation and 
astrogliosis only in Sumf1floxlflox; Nestin-Cre. This observation suggests 
at least two important conclusions: 1) microglial activation and 
astrogliosis are triggered by neuronal dysfunction probably as an 
attempt to clear dying cells and 2) astrogliosis does not represent the 
main mechanism through which astrocytes contribute to the 
neurodegeneration in LSDs, since no signs of astrogliosis were 
observed in Sumf1flOxlflOX; GFAP-Cre mice. Most likely, aberrant 
lysosomal storage in astrocytes hampers more fundamental and 
supportive functions needed for neuronal survival. 
Exhaustive descriptions of the neurological phenotype of the MSD 
mouse model had not been possible in previous studies because of the 
early lethality caused by the complex systemic phenotype (Settembre 
et al., 2007; Settembre et al., 2008a). The generation of the conditional 
Sumf1 mouse line allowed us to overcome this limitation. I observed 
distinct behavioural phenotypes in Sumf1flOxlflox; Nestin-Cre and 
Sumf1flOxlflOX; GFAP-Cre: while they both showed significant impairment 
in motor performance, the deletion of Sumf1 gene only in astrocytes 
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caused hypoactivity and anxiety-like behaviour, whereas its lack in 
both neurons and glia was responsible for hyperactivity and reduced 
learning ability. Interestingly, these neurological symptoms represent 
common features observed in different phases of disease 
manifestations in LSDs: fear and anxiety are generally reported as 
early symptoms, whereas hyperactivity, learning difficulties and 
progressive neurodegeneration occur at a later stage of the disease 
(Staretz-Chacham et aI., 2010) . 
Thus, my data suggest that the progressive neurological deterioration 
found in MSD patients could result from at least two independent 
insults to neurons: one non-autonomous caused by astrocyte 
dysfunction and another, more severe, cell autonomous insult due to 
the lysosomal engulfment and dysfunction. 
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